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ABSTRACT 
CLINICAL IMPLICATIONS OF CIRCULATING CELL-FREE DNA 
IN PATIENTS WITH TISSUE INJURIES 
The existence of cell-free DNA in the plasma and serum has been recognized 
since the mid-twentieth century. In the last two decades, much effort has been spent in 
the development of new diagnostic and prognostic tools. In this thesis, the value of 
cell-free DNA as a prognostic indicator was investigated for patients following 
mechanical trauma and acute stroke. Both situations involve a certain degree of tissue 
injury. 
This thesis investigates the changes in cell-free DNA concentrations after 
trauma. Single blood samples from 103 patients with minor/moderate and major injury 
were studied and significantly higher (10-fold) plasma DNA concentrations were found 
in patients than in 72 healthy controls. Plasma DNA concentrations correlated 
positively with injury severity and were higher in patients who went on to develop 
multiple organ dysfunction syndrome (MODS), and who died. In addition, there was no 
significant difference on plasma DNA concentrations between EDTA or heparin 
anticoagulant. Filtering plasma also had no significant effect on DNA correlations. 
In the second study, serial sampling showed that plasma DNA concentration was 
elevated at 20 minutes after trauma and continued to increase for 3 hours in patients 
with very severe injuries (ISS > 25), and in those patients who later developed organ 
failure (OF). During the first few days after trauma, patients with severe injury and 
MODS exhibited slower overall clearance rates and hence maintained a significantly 
i 
higher level of plasma DNA than patients without MODS. This kinetic difference 
allows the progress of MODS and therapeutic treatments to be monitored. 
The third study investigated the potential value of plasma DNA concentration as 
a prognostic indicator in patients with acute stroke. Plasma DNA concentrations in 
patients who died (either at 28-day or 6-month) were double that of survivors. More 
severely disabled patients (Post-stroke Modified Rankin Score or PR >2) also had a 
significantly higher plasma DNA concentration than those patients with less or no 
disability (PR=0-2). Furthermore, plasma DNA concentration was able to differentiate 
the mortality and disability of patients who had negative neuroimaging. Plasma DNA 
concentrations were significantly higher in patients who died or were severely disabled 
than those patients who survived and were less disabled. Peak plasma DNA 
concentrations occurred 2 days following the onset，which coincided with S-100 and 
neuron-specific enolase (NSE) protein concentrations in other stroke studies. This 
suggested the increased amount of plasma DNA and the proteins may be released from 
same source i.e. the brain. 
Studies in this thesis provide important evidence on the potentially clinical 
usefulness of cell-free circulating DNA in trauma and stroke. 
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Background: Cell-free circulating DNA 
SECTION 1: 
BACKGROUND 
In this section, a thumbnail description of the development, recent applications 
and biology of cell-free circulating DNA in plasma and serum is presented. This is 
followed by two introductory chapters reviewing two common clinical issues: trauma 
and stroke. 
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CHAPTER 1 CELL-FREE CIRCULATING DNA 
DNA and Man 
The past century has witnessed a number of important discoveries in the field of 
molecular biology, the understanding of the molecular basis of heredity, genetic 
variation, and the expression patterns of genetic units known as genes. Genes are units 
of DNA, an abbreviation for a long, double-stranded, zipper-like, helical molecule 
called deoxyribonucleic acid (DNA). 
The study of genetics started in 1865 when Mendel published his results of cross 
breeding experiments conducted on the garden pea Pisum sativum in 1866 in the 
Verhandlungen des naturforschenden Vereines in Brunn, the Proceedings of the Society 
of Natural Sciences in Brno (Brown, 1989). By noting the appearance or disappearance 
of traits, such as pod and flower colour, over several generations, Mendel was able to 
postulate a generalized set of rules governing inheritance (Brown, 1989). He proposed 
that there are discrete units of heredity that are transmitted from generation to 
generation, even though some of these units are not necessarily expressed as an 
observable trait in every generation. Scientists began to look at these units of heredity 
and the ways they transmit to next generations. It was not until 1953, that the structure 
of DNA based on x-ray crystallography studies was clarified by Watson and Crick 
(Watson & Crick, 1953). They were awarded the Nobel Prize in 1962. 
Each strand of DNA is made of repeating nucleotide bases of only four types: 
adenine, cytosine, guanine and thymine. It is the sequence of these nucleotides added 
f p p g p — p w i j i p i p i g p i p p — — ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
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together that make up the human genome. The nucleotides each consist of a phosphate, 
a sugar called deoxyribose and one of the four bases. The bases have distinct binding 
affinities for a specific complimentary base. Adenine and thymine will loosely bond to 
one another when in opposite strands of the helix as will guanine with cytosine. The 
bonding between strands is accomplished via weak hydrogen bonds between the 
complimentary bases. When the strands dissociate the resultant single strands of 
repeating bases contain the information necessary to specify certain proteins. Proteins 
provide both form and function within our cells. 
There are two types of DNA in a human cell - nuclear and mitochondrial. 
Nuclear DNA is linear, occurs in the nucleus and makes up the chromosome. It directly 
controls and takes part in the transmission of genetic information from generations to 
generations. There are two sets of nuclear DNA in the nucleus - one paternal and one 
maternal. Mitochondrial DNA, exists in the mitochondria, is small and circular, 16 500 
base-pairs in length (less than 1/300 000^^  of the total length of nuclear DNA) (Wallace, 
Brown & Lott, 1999). In humans, mitochondrial DNA is inherited strictly from the 
mother (Case & Wallace, 1981; Giles et al., 1980; Hutchison et al., 1974). 
This thesis focuses only on nuclear DNA and the term ‘DNA’ refers to nuclear 
DNA. 
3 
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Cell-free Circulating DNA in Plasma and Serum 
The Discovery and Early Development 
Cell-free DNA in plasma and serum was discovered in clinical studies. Five 
years before the discovery of the double-helical structure of DNA, Mandel and Metais 
discovered that free nucleic acids present in the plasma of both healthy subjects and 
patients with various diseases (Mandel & Metais, 1948). However, at that time the 
findings did not attract much interest. It was not until twenty years later, in the 1960s, 
that cell-free DNA was again observed in the serum of patients with systemic lupus 
erthematosus (SLE) (Tan, Schur & Kunkel, 1966) and other inflammatory diseases 
(Koffler et al, 1973). Many of the early studies of circulating cell-free DNA focused 
on SLE models (Harbeck, Hoffmann & Carr, 1975; Steinman, 1979b; Raptis & Menard, 
1980; Klemp, Meyers & Harley, 1981). 
The breakthrough began in the mid to late 1970，s when high levels of cell-free 
DNA were detected in the serum of cancer patients, especially those with metastases, 
although there was no correlation with the size of the tumour (Leon et al.’ 1975). DNA 
concentrations decreased in most cases after radiotherapy while persistently high or 
increasing DNA concentrations were associated with a lack of response to treatment 
(Leon et al., 1977). These high levels of DNA in the plasma and serum of cancer 
patients were later shown to manifest features of tumour tissues (Stroun et al., 1989). 
More scientists were attracted to investigate this tumour-originated cell-free DNA and 
its potential value in cancer prognosis and monitoring. Tumour-specific markers 
normally found in tumour tissues were subsequently detected in the plasma and serum 
of cancer patients. Oncogene mutations (Sorenson et al., 1994; Vasioukhin et al., 1994) 
and microsatellite alterations (Chen et al., 1996; Nawroz et al., 1996) were the two 
4 
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early markers identified. Epigenetic aberrations were later found (Esteller et al., 1999). 
Nasopharyngeal carcinoma-related Epstein-Barr virus (EBV) DNA was detected in the 
plasma and serum of cancer patients (Mutirangura et al., 1998; Lo et al., 1999c), which 
was thought to be a good marker for prognosis after radiotherapy (Lo et al., 2000a). 
The second bloom started in 1997 when cell-free fetal DNA was discovered by 
Lo et al (Lo et al., 1997). Fetal DNA in maternal circulation was rapidly found to be 
useful for noninvasive prenatal diagnosis. Extensive worldwide studies have been 
carried out since then (Chiu & Lo, 2002). 
Clinical Implications 
Cancers 
For many years, scientists have shown that molecular markers in patients with 
cancer may be used clinically for the detection, prognostication, and monitoring of 
cancers. At the same time, clinicians have desired a simple and non-invasive blood test 
on cancer. Since the neoplastic characteristics of plasma DNA in cancer patients were 
recognized in 1989 (Stroun et al., 1989), a new field of tumour marker research has 
emerged. The somatic genetic alteration in a primary tumour is a potential marker for 
the molecular detection in the serum or plasma of cancer patients. 
• Oncogene mutations 
Genetic studies on cancers have identified a number of genes that are mutated in 
order to bring about the development of cancer or maintain the growth of malignant 
cells. Two main properties of cancer - uncontrolled cell division and the ability to 
spread or metastasize - are the result of genetic alterations. In general, the cell cycle can 
5 
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be regulated in two ways: (1) by genes that normally function to promote cell division, 
and (2) by genes that normally function to suppress cell division. If these genes become 
permanently inactivated or lost through mutation, control over cell division is lost, and 
the cell begins to proliferate in an uncontrollable fashion. Oncogenes will cause cell 
division to occur in an uncontrolled fashion, leading to tumour formation. One major 
class of oncogenes (and proto-oncogenes) are the ras genes, which encode G proteins 
that are located on the inner face of the plasma membrane, where they bind and 
hydrolyse GTP (Alberts et al, 1989). 
Sorenson et al demonstrated the presence of mutated ras sequences in the serum 
of patients with solid tumours (Sorenson et al., 1994). Yi-ras and N-nxy mutation were 
found to be associated with many cancer types (Bos et al., 1987; Hirai et al., 1987; 
Bashey et al., 1992). Yi-ras mutations occur in most colorectal (Minamoto et al., 1995) 
and pancreatic (Almoguera et al., 1988) cancers. Ras mutation is highly specific for 
cancer because it occurs early in the development of a tumour (Johnson & Lo, 2002). 
Studies indicated that K-而 mutations could be detected in the plasma or serum of 
patients with colorectal cancers, the corresponding tumour tissues (Anker et al., 1997; 
de Kok et al., 1997; Kopreski et al., 1997; Hibi et al., 1998; Kopreski et al., 2000), and 
in patients with pancreatic cancers (Mulcahy et al., 1998; Yamada et al., 1998). These 
studies also showed that Y^-ras mutations in plasma or serum were not affected by the 
primary tumour locations and the principal site of metastasis; and did not correlate with 
patient age, sex, histological type and mode of invasion or metastasis. In addition, the 
mutations did not appear in the plasma or serum of healthy subjects, and thus were 
specific for cancer detection. Therefore Y^-ras mutations were considered a potential 
screening test for colorectal cancer (Kopreski et al., 2000). However, the mutations 
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could not be identified in the serum or plasma of every patient with a tumour with a K-
ras mutation (Sidransky, 2000). 
N-ra^ mutations were also found in haematological malignancies such as 
myelodysplastic syndrome and acute myelogenous leukaemia (Vasioukhin et al, 1994). 
N -而 mutations are occasionally found in the cell-free DNA of plasma but absent in the 
DNA of blood cells and bone marrow, thus indicating that plasma DNA analysis may 
sometimes be more sensitive than peripheral or bone marrow blood cells in the 
detection of haematological malignancies. 
Mutated p53, the cancer suppressor gene, has also been detected in the plasma 
and serum of patients with colon, breast and lung cancers (Mayall et al., 1998; Silva et 
al., 1999; Gocke et al., 2000; Gonzalez et al., 2000). This was also shown to be an 
independent prognostic marker for recurrence and metastasis of breast cancer after 
treatment (Shao et al., 2001). 
• Microsatellites 
Microsatellites are repetitive DNA sequences, ranging in size from 2 to 6 base-
pairs and which form variable-length stretches of DNA. Primers can be designed to 
amplify the sequences and may be used as micro satellite markers. Microsatellite 
alterations (for example, loss of heterozygosity (LOH) and microsatellite instability 
(Caims & Sidransky, 1999), are characteristic genetic changes in tumour tissues, and 
therefore tumour tissues can be identified by microsatellite markers (Mao et al, 1994). 
Microsatellite alterations in plasma DNA were first reported in patients with small-cell-
lung (Chen et al., 1996) and head-and-neck (Nawroz et al., 1996) cancer, although not 
detectable in every serum or plasma sample. Moreover, patients having LOH in their 
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plasma and serum are more likely to have invasive tumours, regional spread and distant 
metastases (Fuji war a et al, 1999; Silva et al., 1999; Gonzalez et aL, 2000; Taback et 
aL, 2001a). The positive LOH signal, however, was found to disappear after successful 
therapy (Gonzalez et al., 2000; Sozzi et al., 2001), but reappeared in those patients with 
tumour recurrence (Gonzalez et al., 2000). The alteration has also been detected later in 
the plasma of patients with non-small-cell lung cancer (Sanchez-Cespedes et aL, 1998), 
clear cell renal carcinoma (Goessl et al., 1998), lung cancer (Bruhn et al., 2000), 
melanoma (Taback et al., 2001a) and breast cancer (Taback et al., 2001b). Hence, 
microsatellite alteration is useful in cancer prognostication and monitoring. 
Normal DNA from the lymphocytes, however, may mask microsatellite 
alterations. There are no enrichment techniques as in the case of oncogene mutations 
(Anker et al., 1999). They cannot be precisely identified if most of the serum or plasma 
DNA is derived from normal cells. 
• Epigenetic alterations 
Epigenetic refers to heritable changes in gene expression that do not depend on a 
DNA sequence change (Johnson & Lo, 2002). For example, aberrant methylation of 
cytosine residues of CpG islands in the promoter sequence of tumour suppressor genes 
(DNA methylation) (Esteller, 2000), results in transcriptional silencing and then 
inactivation of that genes. It may then confer growth advantages to the cells that favour 
cancer development. Alternations of DNA methylation, including promoter 
hypermethylation of multiple tumour-related genes is an important mechanism during 
tumorigenesis (Jones & Laird，1999). Numerous aberrant methylated genes have been 
discovered such as pl5 and pl6 which code for two cyclin dependent kinase inhibitor 
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proteins essential in cell cycle. Methylation of pi 6 is common in both lung and liver 
cancer tissues (Johnson & Lo, 2002). In fact, many of these genes play important roles 
either in the regulation of cell cycle or in the pathway of DNA repair (Baylin & 
Herman, 2000). Epigenetic changes can be detected in the tumour tissues of all disease 
stages (Wong et a!., 2000a; Wong et al., 2000b; Wong et aL, 2000c; Hibi et al, 2001). 
Mutated methylation sequences have been detected in plasma and serum of patients 
with lung cancer, liver cancer, breast cancer, oesophagus cancer and leukaemia (Esteller 
et al., 1999; Silva et al., 1999; Wong et al., 2000a; Wong et al., 2000b; Wong et al., 
2000c; Hibi et al., 2001). Furthermore, a close relationship between pi6 methylation 
alterations and a-fetoprotein (a blood protein marker of HCC) concentrations have been 
shown in patients suffering from hepatocellular carcinoma (HCC) (Wong et al., 2000a; 
Wong et aL, 2000b; Wong et al., 2000c). In situations where patients had low a-
fetoprotein concentration, aberrated methylation sequences could also be detected 
(Wong et al., 2000a; Wong et al., 2000b; Wong et al., 2000c). 
Detection of aberrant DNA methylations, especially in the serum or plasma, has 
helped scientists understand the oncogenetic mechanisms underlying tumour 
development as well as helping to develop new and promising molecular assays for 
cancer detection and monitoring (Esteller et al., 1999; Wong et al., 1999; Wong, Lo & 
Johnson, 2001). 
• Viral DNA 
Some cancers are closely associated with certain types of viruses. Two 
particularly well-known viruses are Epstein-Barr vims (EBV) and human 
papillomavirus (HPV). EBV is associated with many types of cancers (Cohen, 2000) 
IlliiiMllffpaMMBPPPIMli—PPPMWi^ ^—M— 
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and is a major cause of nasopharyngeal carcinoma (NPC), whereas HPV is found in 
cervical cancers (Johnson & Lo, 2002). A number of studies have shown that cell-free 
EBV DNA exists in the serum or plasma of NPC patients (Mutirangura et al., 1998; Lo 
et al., 1999c), lymphoid malignancies (Lei et al, 2000; Lei et aL, 2002), adult and 
paediatric Hodgkin's disease (Drouet et al., 1999; Wagner et al., 2001) and gastric 
carcinoma (Lo et al., 2001). The EBV DNA concentrations in serum or plasma of NPC 
patients has proved to be an independent prognostic factor for the disease with regard to 
both recurrence and metastasis after treatment and ultimate mortality, regardless of the 
disease stage (Lo et al., 2000a). Moreover, serial analysis of the EBV DNA 
concentrations in serum or plasma of NPC patients after radiotherapy is a powerful 
method to monitor the post-treatment response and progress of the disease (Lo et al., 
1999b; Lo et al., 2000b). All these studies have suggested that circulating viral DNA, 
particularly with regard to EBV DNA, may be an invaluable tool for cancer monitoring 
and will probably become a routine test for NPC patients thereby directly influencing 
therapeutic decisions (Johnson & Lo, 2002). 
• Rearranged immunoglobulin heavy chain DNA 
Clonal DNA from a rearranged immunoglobulin heavy chain locus was 
detectable in the plasma and serum of 86% patients with non-Hodgkin's lymphoma and 
acute B-precursor lymphoblastic leukemia at diagnosis and before treatment, indicating 
the presence of soluble tumor-derived DNA (Frickhofen et al., 1997). Moreover, 
follow-up studies showed a close correlation of persisting soluble tumor-derived DNA 
with resistant disease or early relapse. This suggested that testing of plasma and serum 
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for tumor-associated DNA may be useful in monitoring the response to treatment 
(Frickhofen et al, 1997). 
Prenatal diagnosis 
There are perhaps many reasons for the need of prenatal diagnosis, but the 
primary aim is to provide peace of mind to couples who fall into the so-called 'at-risk 
groups' such as older mothers or parents who already have children with genetic 
disorders. Traditionally, tools for prenatal diagnosis are divided into two groups: 
invasive methods such as amniocentesis, chorionic villi sampling and fetal blood 
sampling (cordocentesis), and non-invasive methods such as ultrasonography, maternal 
serum screening and fetal cells in maternal blood (Zhang, 2000). The invasive methods 
may pose risks to both fetus and mother. The non-invasive methods, however, are not 
sensitive and specific enough to confirm whether a fetus has a particular defect or not. 
Therefore there is a need to develop both safe and effective prenatal diagnostic tests. 
Lo et al discovered the existence of fetal DNA in the maternal circulation in 
1997 (Lo et al., 1997) when they showed that 7-chromosomal sequences occur in 80% 
serum and plasma samples of pregnant women with male fetuses. In 1998 they also 
found that fetal DNA represented about 3% and 6% of the total maternal DNA in the 
plasma during early (second trimester) and late (third trimester) pregnancy respectively 
(Lo et al., 1998a). Thus maternal plasma provides new valuable sources of fetal genetic 
material for noninvasive prenatal diagnosis. Moreover, with the availability of 
commercial DNA extraction kit and the real-time quantitative PCR technique, SRYFCR 
assay was established (Lo et al., 1998a). Fetal SRY (male-specific sequence) can be 
detected from week of gestation. Sensitivities ranging from 94 - 100% and a 
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specificity of 100% were reported in a number of studies (Lo et al., 1998a; Wei, Sailer 
& Sutherland, 2001; Zhong, Holzgreve & Hahn, 2001). Sekizawa et al (Sekizawa et 
aL, 2001a) further reported a 100% positive predictive value and a 97.5% negative 
predictive value. 
• Sex determination 
Many parents would like to know the sex of the fetus before it is bom. Fetal sex 
can be determined by the detection of presence or absence of Y-chromosomal 
sequences in the maternal plasma (Lo et al., 1997). Positive signal of Y-chromosomal 
sequence indicates a male fetus whereas female fetus will give a negative signal (Lo et 
al., 1997). 
From the clinical point of view, the gender of a fetus gives an additional piece of 
information on the health status of the baby. For example, if a pregnant woman is 
known to be carrier of an X-linked recessive trait, there is a 50% risk of a sex-linked 
genetic disorder if a male fetus is present (Chiu & Lo, 2002), and further invasive tests 
may be required for confirmation. Rijnders et al (Rijnders et al., 2001) also 
demonstrated the usefulness of fetal sex determination in the evaluation of prenatal 
therapy on fetuses suspected of congenital adrenal hyperplasia. Prenatal 
dexamethasone therapy may be necessary to female fetus to prevent virilization, which 
is unnecessary for affected male fetuses. 
• RhD genotyping 
Fetal rhesus D (RhD) genotyping is the first non-invasive prenatal diagnostic 
procedure to be adopted in routine clinical screening by the British National Blood 
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service, based on the fetal DNA in maternal plasma and serum analysis (Chiu & Lo, 
2002). The assay makes use of the differences between paternally-inherited fetal traits 
and the maternal DNA. RhD gene was correctly detected in all plasma or serum of 
RhD-negative pregnant women who carried RhD-positive fetuses of gestational age 16-
17 weeks, using conventional PCR (Faas et al., 1998). Lo et al obtained similar results 
by using real-time quantitative PCR (Lo et al., 1998a). Further modifications to the 
real-time quantitative PCR assay were carried out by different groups to maximize the 
reliability as well as the accuracy (Finning, Martin & Avent, 2001; Zhong, Holzgreve & 
Hahn, 2001). 
• Hereditary disease diagnosis 
The ability to diagnose hereditary diseases in the fetus as early as possible 
during pregnancy is one of the fundamental elements in the scientific study of prenatal 
diagnosis. The approach makes use of the fact that paternally-inherited fetal genes or 
mutations can be distinguished from maternal genes or mutations. Myotonic dystrophy 
(Amicucci et al., 2000) and achondroplasia (Saito et al., 2000) were the first two 
paternally inherited autosomal-dominant disorders detected from the maternal plasma. 
Defective genes were detected in the plasma of normal pregnant women whose 
husbands were affected, thus indicating that the conceived fetuses were affected. For 
autosomal-recessive disorders such as beta-thalassaemia (Chiu et al., 2002b) and 
congenital adrenal hyperplasia (Chiu et al., 2002a), the diagnosis is based on exclusion, 
i.e. the absence of paternally inherited mutations in the maternal plasma excludes the 
chance of having two recessive genes and therefore the fetus is free from the disease. 
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Pregnancy abnormalities 
Real-time quantitative PGR technique allows the quantitation of fetal DNA 
during different gestational stages, by measuring the concentration of Y-sequences in 
the maternal plasma of pregnant women carrying male fetuses (Lo et al., 1998a). Fetal 
DNA concentration in maternal plasma increases with gestational stage in normal 
pregnancy (Lo et al, 1998a). Extraordinarily high concentrations of fetal DNA have 
been observed in abnormal pregnancies compared with normal pregnancy such as 
preterm labor (Leung et al., 1998), preeclampsia (Lo et al., 1999e; Leung et al., 2001; 
Lau et al., 2002), idiopathic polyhydramnios (Zhong et al., 2000c), hyperemesis 
gravidarum (Sekizawa et al., 2001b) and in mothers carrying aneuploid fetuses (Lo et 
al., 1999d; Zhong et al., 2000a). Hence fetal DNA in maternal plasma or serum can be 
a non-specific marker for abnormal pregnancy monitoring and prediction. 
As long as the monitoring of abnormal pregnancies was based on the detection 
of Y-sequence in the maternal plasma, it limited the applications to the pregnancies of 
female fetuses. Tang et al (Tang et al., 1999) have detected fetal-derived paternally 
inherited X-chromosome by detecting the short tandem repeat (STR) polymorphisms on 
the X-chromosome. This approach allowed the possibility to detect fetal DNA of 
female fetuses and to study X-linked diseases. Moreover, the ability to differentiate the 
methylation status of the fetal DNA from the maternal DNA allowed genetically 
identical paternally inherited fetal alleles to be distinguished from maternal alleles, and 
also to distinguish maternally inherited fetal alleles from maternal plasma (Poon et al., 
2002). Thus the role of plasma fetal DNA analysis in prenatal diagnosis is increasing. 
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Organ transplantation 
The concept of plasma DNA chimerism i.e. the presence of genetically different 
DNA in the circulation of an individual such as tumour-originated DNA in plasma of 
cancer patients and the fetal DNA in maternal plasma (Lo, 2001), has extended to organ 
transplantation. Based on a similar approach to that of prenatal analysis, Lo et al first 
reported the presence of male specific sequences in the plasma of female patients after 
receiving kidney or liver organ transplants from male donors (Lo et al., 1998b). Plasma 
DNA of male origin was observed in 100% and 82% of female recipients with male 
kidneys and livers respectively, compared to only 83% and 24% of cellular counterpart 
in the same transplanted subjects (Lo et al., 1998b). These 'non-host' DNA in plasma 
may be used as a marker for graft rejection after organ transplantation because graft 
rejection will increase cell death in the transplanted organs, causing the release of 
donor-specific DNA into the bloodstream. This is analogous to the phenomenon of the 
presence of donor-derived cells in body tissues and peripheral blood of recipients 
(Starzl et al., 1992). Other post-transplantation tissue-damage related complications 
like graft infection and neoplastic involvement of the graft could also be monitored (Lo 
et al, 1998b). 
Trauma and post-traumatic complications 
There is much evidence to show the usefulness of "non-host" DNA in the 
plasma and serum in the diagnosis and prognosis of various clinical conditions, that 
cell-free DNA is generated in healthy body and also plays an important role in our 
health status. High levels of circulating cell-free DNA have been observed in patients 
suffering from different diseases such as SLE (Tan, Schur & Kunkel, 1966; Koffler et 
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al, 1973; Steinman, 1979a), cancer (Leon et al., 1975; Leon et aL, 1977), sepsis 
(Martins, Kawamura & Carvalho，2000) and myocardial infarction (Chang et al., 2003). 
All these scenarios involve cell death, either necrosis or apoptosis (Klemp, Meyers & 
Harley, 1981; Stroun et al., 2000; Martins, Kawamura & Carvalho, 2000; Chang et al., 
2003), which has prompted Lo et al to the investigate changes in cell-free DNA levels 
after trauma (Lo et al., 2000c). Cell-free DNA in plasma of trauma patients is elevated 
significantly within 4 hours (median 1 hour) after the event of injury (Lo et al., 2000c), 
correlates with injury severity, the later development of organ failure and mortality. 
Potentially useful prediction guidelines for early risk-stratification of post-traumatic 
complications has been developed by combining plasma DNA values and other 
predictors, for example, injury severity scores, leucocyte count, shock index and 
aspartate transaminase (Rainer et al., 2000; Rainer, 2001). 
Origin, Mechanisms and Characteristics 
Before cell-free DNA in the plasma and serum was proved to be clinically 
useful, scientists sought to elucidate its origin. It was thought to be derived from 
lymphocytes or other nucleated cells (Stroun et al., 2000). Cell-free DNA in serum 
may also be due to the liberation from leucocytes during the clotting process (Davis & 
Davis, 1973; Cox & Gokcen, 1976) as obviously different DNA concentrations were 
observed between plasma and serum. But this leucocyte DNA was said to form only a 
non-significant portion (Jahr et al., 2001). On the other hand, cell-free DNA released 
from eukaryotic cells has been demonstrated in both amphibian organs (Stroun & 
Anker, 1972; Stroun et al., 1977) and human lymphocytes when stimulated with 
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antigens or mitogens (Rogers, 1976), or unstimulated (Anker, Stroun & Maurice, 1975; 
Anker, Stroun & Maurice, 1976; Olsen & Harris, 1974; Hoessli et al., 1977). 
In 1989, substantial proportions of cell-free DNA were discovered in the plasma 
and serum of cancer patients, shared the characteristics of tumour cells and it was 
postulated that much of the DNA originated from tumor cells (Stroun et al., 1989). The 
mechanisms for shedding of tumour DNA into the circulation remained controversial 
(Stroun et al., 2000). Four possible mechanisms have been proposed (Stroun et al., 
2000): (1) lysis of circulating cancer cells or micrometastases. However, the number of 
cell-free DNA in the circulation was found to be much higher than the circulating 
cancer cells. (2) Tumour necrosis. Against this is the finding that DNA levels decrease 
up to 90% after radiation therapy and it has not been possible to demonstrate an initial 
surge following radiotherapy (Leon et al., 1977). However, Lo et al (Lo et al., 2000b) 
has successfully demonstrated an initial rise in circulating tumour-derived EBV DNA in 
all NPC patients post-treatment, provided that the blood sampling is done frequently 
enough (e.g. weekly). This recent work provides evidence to support the cell death 
hypothesis. (3) Apoptosis. Cell-free DNA in the plasma and serum of cancer patients 
showed ladder pattern after electrophoresis that is a typical feature of apoptosis (Stroun 
et al., 1987; Foumie et al., 1995; Giacona et al., 1998; Jahr et al., 2001). At least a 
portion of the DNA was derived from the apoptosis of tumour cells (Anker et al., 1999). 
Against this possibility are the findings firstly that apoptosis is a mechanism supposedly 
lost by proliferating cancer cells and great efforts are needed to restore programmed cell 
death in malignant cells (Stroun et aL, 2000). Secondly, cell death products particularly 
those containing DNA such as apoptotic bodies are usually cleared in situ by epithelial 
cells and macrophages without any inflammatory effect (Savill et al., 1993). (4) 
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Spontaneous and active release of DNA. Tumour cells are hypothesized to release 
DNA into the blood stream in an active way (Anker et al., 1999). This was prompted 
by the previous studies that circulating cell-free DNA was released actively by 
lymphocytes and frog auricles in vitro (Anker, Stroun & Maurice, 1975; Stroun & 
Anker, 1972; Rogers et al., 1972b). Newly synthesized DNA was found to be released 
preferentially (Stroun & Anker, 1972; Anker, Stroun & Maurice, 1975; Rogers et al., 
1972a) which is against the hypothesis of apoptosis. Anker et al also observed that 
cancer cells in culture release more DNA than normal cells (Anker et al., 1999), a 
phenomenon to support the notion of active release. 
Fetal DNA occurs in the circulation of maternal plasma and serum, evidenced 
by the present of Y-chromosomal sequences in the plasma and serum of pregnant 
women with male fetuses (Lo et al., 1997). Yet, the origin of the fetal DNA remains to 
be determined. It was first proposed the fetal DNA in the maternal circulation comes 
from fetal nucleated cells in the maternal blood (Lo et al., 1998a; Bianchi, 1998). This 
was further reflected in recent findings that a large number of fetal cells undergo 
apoptosis in maternal blood (Sekizawa et al., 2000; Kolialexi et al., 2001) and plasma 
(van Wijk et al., 2000). However, the amount of nucleated fetal cells in the maternal 
circulation is low: 0.0035 - 0.008% (Hamada et al., 1993), and it is therefore hard to 
explain how these rare cells could contribute to such high levels of fetal DNA in the 
maternal plasma (2.33 - 11.4% of total cell-free plasma DNA in the maternal plasma) 
as well as the rapid turnover of fetal DNA as indicated by the fetal DNA clearance rate 
after delivery (Lo et al., 1999f). The second possibility for the cell-free fetal DNA in 
maternal plasma and serum may be directly released from fetal tissues to maternal 
circulation via the fetomatemal interface (Lo et al, 1998a; Bianchi, 1998) since fetal 
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DNA concentration was found to increase with gestation age (Lo et al., 1998a). 
Apoptotic cells in fetal tissues also increase with gestation age (Smith, Baker & 
Symonds, 1997). Moreover, high levels of fetal DNA in the maternal plasma of 
preeclampsia cases were also found to be consistent with an increased apoptosis in the 
fetal compartment (Allaire et al., 2000). On the other hand, Zhong et al found that the 
release of fetal DNA was not coupled with the release of maternal DNA (Zhong et al., 
2000b). 
Clearance of circulating DNA has been well demonstrated in post-delivery 
pregnant women, both in normal pregnancies (Lo et al., 1999f) and in those patients 
who developed preeclampsia (Lau et al., 2002). The mean time for 50% reduction of 
plasma fetal DNA was 16.3 minutes (range 4 - 3 0 minutes) and no fetal DNA was 
detected after 2 hours postpartum (Lo et al., 1999f). In contrast, the clearance rate in 
the preeclamptic women was 4 times longer than the healthy women (Lau et al., 2002). 
The clearance of fetal DNA in maternal plasma consists of two phases: an initial more 
rapid phase, followed by a slower phase, suggesting more than one mechanism may be 
involved (Lo et al., 1999f; Lau et al., 2002). Kidney (Tsumita & Iwanaga, 1963) and 
liver (Emlen & Mannik, 1984) were the two major organs suggested to be involved in 
the removal of circulating DNA. This may explain the impaired clearance in 
preeclamptic women since organ systems may be affected and damaged by the disorder. 
The presence of nucleases in the plasma and serum was also thought to be taken part in 
the degradation of the circulating DNA (Paoletti, Gosse & LePecq, 1963; Gosse et al., 
1965; Emlen & Mannik，1984). However, it was shown by Lo et al that nucleases in 
the plasma only play a partial role in the removal of circulating fetal DNA (Lo et al., 
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1999f). Besides, the experiments carried out by the earlier groups could not be used to 
fully explain the situation in vivo because they used foreign and purified DNA. 
The clearance and temporal variation of plasma or serum tumor derived EBV 
DNA after treatment is important for prognosis and for monitoring cancer recurrence 
(Lo et al., 1999b; Lo et al., 2000b; Lei et al., 2000). The plasma or serum EBV DNA 
after radiotherapy decreased significantly in most cases, and a gradual increase in EBV 
DNA concentrations was observed in those patients who developed tumour recurrence 
(Lo et al., 1999b; Lei et al., 2000). In fact, within the first week of post-treatment, an 
initial short-duration rise of EBV DNA concentration could be detected in all cases, 
followed by the reduction (Lo et al., 2000b). The initial rise of EBV DNA coincide the 
hypothesis of radiation induced tumour cell death (Lo et al., 2000b). 
In order to prove the hypothesis that circulating DNA in the plasma and serum is 
of haematopoietic origin, Lui et al conducted a novel study using a sex-mismatched 
bone marrow transplantation model (Lui et al., 2002). The results demonstrated that 
cell-free DNA in the circulation was predominantly haematopioetic origin. Following 
the same approach, a study later revealed non-haematopioetic originated DNA 
accounted for only a minority of the free DNA, using heart, liver and renal sex-
mismatched organ transplantation models (Lui et al., 2003). Another study by Lui et al 
in 2002 (Lui, Chik & Lo, 2002) also investigated and excluded the possibilities of in 
vitro induced cell-free DNA in plasma and serum. Several commom pre-analytical 
variables such as the use of syringes and needles in the blood taken procedures, time 
delay in the blood sample processing, and effect of centrifugation were not found to be 
attributable to the DNA concentration in the blood samples (Lui et al., 2002). 
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Cell-free DNA in the circulation of normal subjects has different characteristics 
to those with diseases. Circulating DNA consists of both double-stranded and single-
stranded DNA (Cox & Gokcen, 1976). Double-stranded and single-stranded DNA were 
I 
present in the circulation in approximately equal proportion in normal individuals but 
vary significantly in many diseases such as cancer (Cox & Gokcen, 1976). Stroun et al 
have shown that cell-free DNA in the plasma and serum of cancer patients is double-
stranded in nature (Stroun et al., 1987). Cell-free DNA was also found to be smaller 
than cellular DNA (Anker, Stroun & Maurice, 1975) and fragmented (Giacona et al., 
1998). Giacona et al also found that small pieces of cell-free DNA were more 
prominent in the plasma of cancer patients than in the healthy controls. They also 
pointed out that the amount of small size DNA was probably derived from apoptosis in 
neoplastic cells. Chan et al also observed that plasma EBV DNA from NPC patients 
mainly consisted of short DNA fragments (Chan et al., 2003). 
High stability of cell-free DNA was observed in the plasma and serum in vitro, 
although with the existence of nucleases (Tan, Schur & Kunkel, 1966; Koffler et al., 
1973; Klemp, Meyers & Harley, 1981). This might be due to the complexity of DNA 
with proteins in the circulation protected from nucleases degradation. Cell-free DNA 
was assumed to be of cellular origin and therefore at least some of them should be 
composed of DNA that was connected to histone and non-histone proteins and 
ribonucleic acid (RNA) (Dermin, 1979). 
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Methods of Analysis 
Extraction methods 
Cell-free DNA is present in minute amounts in the plasma and serum, about 57 
ng per mL serum (Wu et al, 2002). The DNA is mixed with large amount of proteins 
and/or residual blood cells in the plasma or serum. Moreover, a substantial amount of 
the cell-free DNA is in fact complexed with histone- and non-histone proteins because 
they are assumed to be of cellular origin (Dennin, 1979). In order for these 'rare' DNA 
to be analysed (e.g. by RTQ-PCR), they have to be extracted out from the mixture 
(plasma or serum), purified and concentrated. 
Methods involved phenol/chloroform have been commonly used. Sodium 
dodecyl sulfate (SDS)/proteinase K digestion of plasma or serum followed by 
phenol/chloroform extraction is claimed to produce the best DNA quality and yield 
(Jen, Wu & Sidransky, 2000). Currently, there are quite a number of commercial kits 
available for DNA extraction which require no organic solvent and save time. 
Detection methods 
During the early years, different methods were established and used by different 
groups for studying and quantifying cell-free circulating DNA. Some examples 
included diphenylamine assay (Giles & Myers 1965), ethidium bromide assay (Kamm 
& Smith, 1972), counterimmunoelectrophoresis (CIE) (Davis & Davis, 1973), RNA-
DNA hybridization (Steinman, 1975), radioimmunoassay (RIA) (Cox & Gokcen, 1976; 
Leon et al., 1977), electron microscopy (Dennin, 1979), and UV absorbance (Jachertz et 
al 1979). 
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By using the above methods, the presence of cell-free DNA in the plasma and 
serum of normal subjects has become a conflicting issue (Kamm & Smith, 1972; 
Steinman, 1975; Dennin, 1979). Some studies reported that cell-free DNA was not 
present in circulation of normal subjects (Tan, Schur & Kunkel, 1966; Perlin & Moquin, 
1972; Davis & Davis, 1973). Such negative findings were later thought to be due to the 
low sensitivity and specificity of the methods used (Cox & Gokcen, 1976). 
A novel, more sensitive method was developed in the late 80s and 90s for the 
detection of minute quantities of DNA in a sample. The method was based on the 
polymerase chain reaction (PGR) which was invented in the mid 80s (Saiki et al., 
1985). PGR is a powerful technique for amplifying DNA from very minute quantities. 
Different modifications of PCR were developed in the past decade to fullfil various 
purposes. For examples, nested PCR was designed for analyzing minute amounts of 
cell-free DNA such as fetal DNA in the maternal plasma (Smid et al., 1999), with the 
shortcoming of having high risk of cross-contamination when PCR product is 
transferred from one phase to the next (Lo et al, 1989). The amplification refractory 
mutation system (ARMS) was used for the detection of known mutations of DNA in 
plasma and serum (Newton et al, 1989). Mutated DNA sequences, for example, K-nxs, 
mutations of tumour sample, can be selectively amplified (Yamada et al, 1998). 
Microsatellite (MS) analysis (the tumor-derived genetic alteration) can be done by using 
a selected panel of MS-specific markers (Beau-Faller ct al, 2003). Methylation-
specific PCR (MSP) is a special type of PCR developed for analysis of DNA 
methylation patterns (Herman et al.’ 1996) such as the hypermethylation of tumour 
suppressor genes. Quantitative PCR, on the other hand, aims to offer DNA 
quantitation. Different systems of quantitative PCR has been established，like 
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competitive PGR (Coutelle, 1991; Siebert & Larrick, 1992). However, those early 
systems required post-PCR manipulation for DNA quantifications. 
Real-time Quantitative PCR 
Higuchi et al (Higuchi et al., 1992; Higuchi et aL, 1993) pioneered the analysis 
of PCR kinetics by constructing a system that detects PCR products as they accumulate, 
so called 'real-time' system, in order to eliminate all post-PCR manipulation. And until 
1996, a new real-time quantitative PCR using a fluorescent TaqMan assay employs a 
dual-labelled fluorogenic hybridization probe was invented (Heid et al., 1996). The 
chances for carry-over contamination with this system is highly reduced and the 
throughput increases significantly. 
Real-time quantitative PCR has been applied in all studies of this thesis for cell-
free circulating DNA measurement. Commercial extraction kits have been used for 
DNA extraction. Details are described in Chapter 5. 
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CHAPTER 2 TRAUMA AND ORGAN FAILURE 
Trauma and Society 
Trauma may happen anywhere, at any time, be accidental or non-accidental, and 
may affect either sex and all ages. Trauma is one of the leading causes of death in 
people up to middle-age. Murray and Lopez (Murray & Lopez, 1997) reported in 1990 
that deaths due to injuries were 5.1 million and that this accounted for 10% of global 
mortality. Of all deaths caused by injury, road-traffic accidents were ranked the ninth 
leading cause of death. Industrialization, urbanization and affluency are believed to be 
the three major variables causing an increase in number and variety of injuries. High-
speed transportation technology and the density and diversity of freeway traffic have 
caused an unprecedented numbers of fatalities (Oakes, 1979). 
In Hong Kong, injury together with poisoning is the fifth cause of death. The 
number of deaths has increased steadily from 1,670 in 1996 to 1,906 in 2000 (Census 
and Statistics Department, 2001). 
The cost for injury is very high and trauma has become a social burden. In 
United States, the medical expenditures on injuries amounted to 64.7 billion US dollars 
in 1987 and 8.3% of total personal health care spending in 1993 (Alpar & Gosling, 
1999). Death and disability was also enormous: 75 million US dollars a day in the 
United States (Tmnkey, 1988). In the United Kingdom, the Department of Transport 
estimated that in 1995 the total cost on fatal, serious and minor accidents occurring on 
the roads was £13.3 billion (Alpar & Gosling, 1999). 
........................... . …… . 
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Trunkey (Trunkey, 1988) also pointed out that at least half of these deaths are 
needless and preventable. During the past several decades, in well-developed countries 
like those of North America and in Europe, many improvements have been made by the 
implementation of trauma systems or centres, together with the training of medical 
professionals in trauma management to reduce unnecessary mortality, morbidity and 
disability due to injuries. Educational programs were also made to educate the public 
on injury preventions. (Cobb, 1991; Eastman, 1992; Braslow & Snyder, 1993; Trunkey, 
2000) 
The Problem of Organ Failure 
While the modem trauma care system is successful in saving lives in the 
emergency room, some patients go on to develop infections and/or organ failure (OF) 
that may eventually result in death. Sometimes one or more organs fail. Where the 
condition is known as multiple organ dysfunction syndrome (MODS). The incidence of 
MODS after major trauma ranges from 11 to 25%, and the mortality ranges from 50 to 
100% (Faist et al., 1983). The word ‘dysfunction’ is thought to better represent the 
gradation in insult that may occur (Moore, Moore & Read, 1993). Of all vital organs, 
the lungs are usually the first to fail, resulting in acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS). Trauma has long been recognized as one of the 
major causes of MODS, ALI and ARDS (Baue, 1975; Eiseman, Beart & Norton, 1977; 
Fry et al., 1980), while MODS itself is the leading cause of morbidity and mortality for 
patients in the intensive care unit (Marshall et al., 1995). In patients suffering from 
severe trauma, they will have 15% risk of developing MODS and a 5-25% risk of 
developing ARDS (Fowler et al., 1983; Hudson et al., 1995; Smail et al., 1995; Moore 
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et al., 1996). Mortality increases with ARBS and reaches 100% when more than four 
organs fail (Pepe et aL, 1982; Fowler et al., 1983; Goris et al., 1985; Montgomery et al., 
1985). 
Definitions 
Clinical investigation of ARBS, ALI and MODS has suffered because of 
imprecise (Moore, Moore & Read, 1993; Cryer, 2000) and non-uniform definitions. 
For the purpose of this thesis the following definitions apply. 
• OF 
This is defined as a MODS score > 1 at any time from arrival at the emergency 
department to the end of the study. It therefore includes single and multiple organ 
failure (MODS) occurring at any time after injury. 
• MODS 
For the purpose of this study a quantitative definition using Goris' organ failure 
score is used (Goris et al., 1985). The principle organ-systems involved in the 
development of MODS are pulmonary, renal, hepatic, gastrointestinal, cardiac, 
neurological and haematological. Each organ/system is scored from 0 to 2, either as 
normal (0), moderate (1) or severe (2) organ failure. The scores are summed to give a 
final MODS score ranging from 0 to 14. For this thesis MODS is defined as a multiple 
organ failure (MOF) score of > 2, and therefore includes at least two failing organs. 
MODS is not diagnosed until >48 hours after injury onset in order to exclude the 
possibility that some of the changes might be due to direct injury rather than an 
inflammatory response. Detailed criteria for MODS diagnosis using Goris,s organ 
failure score are available in Appendix 1 • 
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• ARDS and ALI 
ARBS is a catastrophic form of inflammatory pulmonary injury. It was first 
described by Ashbaugh in 1967 (Ashbaugh, 1967) and like MODS, has been immersed 
in controversy regarding its definition, pathogenesis, classification of onset and severity, 
management and prognosis ((Rinaldo & Rogers, 1982). A new consensus definition 
was formulated for clinical, experimental and pathological purpose (Bernard et al., 
1994). The onset is acute and persistent such that it can be differentiated from chronic 
lung diseases. Together with ALI, both are syndromes of inflammation and increased 
permeability that are associated with a constellation of clinical, radiological and 
physiological abnormalities. They result from inflammatory cell-mediated endothelial 
injury with consequent disruption of capillary and alveolar integrity, and filling of the 
alveoli with protein-rich fluid (Rinaldo & Rogers, 1982; Bernard et al., 1994). ARDS 
and ALI are pathologically similar and differ only in degree of injury and 
ventilation/perfusion mismatch. Detailed criteria for ARDS and ALI are available in 
Appendix 2. 
Pathogenesis 
The pathogenesis of ARDS and MOF (or MODS), especially after injury, is still 
uncertain. Early in the twentieth century, W.B. Cannon in 1919 recognized that the 
problem of organ failure after injury was caused by an unknown factor (Trunkey 1988). 
Cannon proposed that the toxic factor was given off by "smashed and dying" tissue and 
probably came from the wound. He also observed that the factor could cause injuries in 
organs remote from the primary injury. A number of hypotheses and studies on the 
pathogensis of MOF were conducted between the 1960s and 1990s (Moore, Moore & 
Read，1993). Two stages can be observed. From the 60s to mid 80s, studies suggested 
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that both ARBS and MOF were the consequence of sepsis (Balk & Bone, 1989; Ayres, 
1985), a term to describe systemic response to infection. But since the mid 80’ s, studies 
began to demonstrate that ARDS an MOF can occur in the absence of infection (Goris 
et al, 1985; Waydhas et aL, 1992; Sauaia et al., 1993). Researchers believed that 
traumatic insult (especially more severe and massive injury) will induce systemic 
inflammatory response syndrome (SIRS) which will lead to OF, and will evolve into 
overt MOF. 
Inflammation 
Our body's inflammatory response is believed to be physiologically beneficial: 
inflammatory mediators or molecules such as cytokines are 'designed' to control 
pathogens and remove damaged tissue from wounds. Acute inflammation is induced by 
activation of direct or indirect pathway of the complement system by tissue trauma, 
Escherichia coli, endotoxin, bums, pancreatic enzymes, etc (Goldstein et al., 1977). 
Products of the complement cascade will then induce neutrophils to aggregate and 
marginate in the critical area, and produce prostaglandins (Goldstein et al., 1977; 
Wedmore & Williams, 1981) and toxic oxygen radicals (Kuehl, Humes & Torchiana, 
1979). The toxic content released by activated neutrophil will result in endothelial 
damage, increased permeability, and edema - local inflammation. Localized 
inflammation is tightly controlled by the body at the site of injury. However, when the 
injury is overwhelming, the inflammatory reaction will no longer be limited to original 
sites where the problem occurs, but will affect other distant sites systemically (Partick et 
al., 1999), a condition clinically identified as SIRS (Davis & Hagen, 1997). The 
inflammatory mediators do not make a distinction between cleaning up damaged and 
undamaged tissue once large amounts of them appear in the bloodstream. They may 
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become destructive rather than protective. They gradually damage the end organs they 
reach and cause organ dysfunction, resulting in MOF. Nuytinck et al (Nuytinck et al, 
1988) have demonstrated from autopsy studies on dead patients who suffered from 
posttraumatic MOF the signs of generalized inflammation and tissue damage with 
increases in weights in those organs not primarily injured. 
With particular regard to ARDS and ALI, the inflammatory processes involved 
are the result of a complex interplay of cellular (leucoctye) and non-cellular (cytokine) 
components that are carefully controlled by intercellular communication (Rainer, 2000). 
In the lung, disruption of alveolar integrity results in filling of the alveolae with protein-
rich fluid and ventilation mismatch. Neutrophils, their secretory products and cytokines 
are responsible for chemotaxis and are present in the bronchoalveolar lavage fluid of 
most patients that develop ARDS (Weiland et al., 1986). Early activation of pulmonary 
vascular endothelium and circulating neutrophils results in upregulation of adhesion 
molecules, which are responsible for leucocyte-endothelial adhesion, migration, 
sequestration and subsequent accumulation in alveolar spaces (Rainer, 2000). 
Predictions 
In the last decade, many extensive and expensive trials had been conducted in 
patients suffering from MOF. Trials were based on the treatment against early SIRS 
and monoclonal antibodies to block endotoxin and cytokines. However, the results 
were not encouraging, partly because of an inability to identify patients at risk of 
developing MOF early enough (Sauaia et al., 1998). Eichacker and his colleagues have 
found that the attempt to block these factors may not have been conducted in the most 
effective manner (Eichacker et al., 2002). The agents that blocked individual 
inflammatory factors were most beneficial in the most lethal conditions and least 
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beneficial in the least lethal (Eichacker et al., 2002). The lack of early prediction rules 
for MODS/ARDS has meant that it is not possible to select and target high-risk cases 
with suitable interventions before organ failure begins, and clinicians have had to wait 
until OF is well developed before including subjects in trials (Rainer, 2000). Sauaia et 
al (Sauaia et al., 1998) have developed a prediction model for MOF as early as 12 hours 
after injury, based on clinical risk factors. The sensitivity and specificity were found to 
be 63% and 84% respectively; and a positive predictive value of 48%. Criticism has 
been revealed at these models that ‘by the time you predict it, it's already there' (Cryer 
et al, 1999). Thus, it would be useful to develop new assays and prediction models 
which allow earlier risk stratification. 
Trauma Scoring Systems 
Organ failure often occurs in patients who have suffered from severe trauma. 
The grading of injuries is therefore crucial for the stratification of trauma patients for 
appropriate treatments. An ideal scoring system should provide an accurate description 
of all injuries, define severity indices for each injury, and be acceptable and practical for 
use by all those involved in the care of trauma victims. In turn, an accurate scoring 
system can be essential for conducting outcome studies on the treatment, prevention, 
and prognosis of trauma patients (Brenneman et al., 1998). The method for measuring 
injury severity started in 1943 when DeHaven created a scale to study airplane crash 
injuries (Brenneman et al., 1998). 
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Abbreviated Injury Scale (AIS) 
In 1971，AIS was introduced by the Joint Committee on Injury Scaling, 
composed of members of the American Medical Association (AMA), The American 
Association for Automotive Medicine (AAAM), and the Society of Automotive 
Engineers (SAE) (Mackenzie, Shapiro & Eastham, 1985). It was originally developed 
for motor vehicle injury study. Since its introduction, a number of modifications have 
been made. The most updated edition was established in 1990 (Association for the 
Advancement of Automative Medicine, 1990). Its scope has been increasing expanded 
to include other injuries. 
The AIS is an anatomically-based scale for rating severity of injuries 
(Mackenzie, Shapiro & Eastham, 1985). The scale ranges from 1 (minor injury) to 6 
(maximum and lethal injury), on individual injuries in different body regions. The 
major limition is its inability to compare patients with multiple injuries (Baker et al., 
1974; Mackenzie, Shapiro & Eastham, 1985; Brenneman et al., 1998). 
Injury Severity Score (ISS) 
Baker et al (Baker et al., 1974) introduced the ISS to provide a mean of 
summarizing multiple injuries in a single patient. It is defined as the sum of squares of 
the highest AIS grades in the three most severly injured body regions. It ranges from 1 
to 75. Six body regions are defined: head and neck, face, thorax, abdomen and pelvis, 
extremities, and external. Only one injury per body region is allowed. 
The ISS has been generally recognized as the “gold standard" for anatomical 
injury severity assessment (Rutledge et al., 1997) and is particular useful for evaluating 
blunt trauma with multiple injuries. Moreover, ISS has also been used for the 
prediction of mortality and organ failure after trauma (Baker et al., 1974; Offner, 2002). 
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Nevertheless, ISS has several limitations (Offner，2002): (1) its inability to account for 
multiple injuries to the same body region. It limits the total number of contributing 
injuries to only three. This seriously impairs the usefulness of the ISS in patients with 
penetrating injuries and in those with multiple limb injury. (2) The ISS weighs injuries 
to each body region equally, ignoring the enhanced importance of head injuries in 
mortality from trauma. (3) Mortality is not strictly an increasing function of the ISS. 
These reduce the predictive ability of the ISS. 
Other scoring systems 
In addition to the anatomical scoring systems, there are physiological injury 
severity scores that depend on physiological parameters. The two common scores are 
Revised Trauma Score (RTS) (Boyd, Tolson & Copes, 1987) and Acute Physiology and 
Chronic Health Evaluation (APACHE) (Knaus et al., 1985). Combined anatomic and 
physiological injury severity scores were also developed to improve the predictive 
capability. Champion and coworkers (Champion, Copes & Sacco, 1990) have 
developed two combined models: Trauma and Injury Severity Score (TRISS) and A 
Severity Characterization of Trauma (ASCOT). 
Although the ISS is not perfect, it is still a widely used severity model in clinical 
practices and researches. 
Definition of Trauma 
There is a lack of precise definition of “trauma’’，and untested extrapolations are 
commonly made between the effects of surgical, thermal and traumatic injury (Cocks, 
1993). General surgical studies are frequently controlled elective events in which the 
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patient is prepared and fasted prior to the ‘injury’ of surgery, and pre-operative (pre-
injury) stress is modified by pre-medication. The use of anaesthetic and other agents 
may further modify the patient's response mechanisms to the 'injury'. This constrasts 
with trauma where the patient is usually conscious up to the moment of, and unprepared 
for, the injury. The briefest of warnings is followed by a traumatic event, which is not 
modified by pre-medication, and the patient is not fasted. Trauma patients are 
frequently younger and fitter, often with no pre-morbid medical history while surgical 
patients may often be older and have pre-existing illness (Rainer, 2000). Thermal injury 
is also strikingly different, frequently involving a gross disruption to external barriers to 
infection (the skin) which is not paralleled in trauma or surgery. Trauma therefore 
merits study in its own right. The processes that lead to post-traumatic complications 
start within minutes to hours after injury and provide a well-defined window of 
opportunity in which to study individuals in whom inflammatory mechanisms may 
under- or over-respond prior to the development of infection or organ failure (Rainer, 
2000). 
For the purposes of this research study, "trauma" is taken to mean any injury to 
the human body caused by the application of kinetic energy (Cocks, 1993). This 




CHAPTER 3 STROKE 
The Burden of Stroke 
Stroke is a common cause of death and disability worldwide. It ranked as the 
second leading cause of all deaths worldwide in 1990, accounted for 4.4 million victims 
(Murray & Lopez, 1997) and is also currently the leading cause of brain injury in adults 
(Broderick et al., 1992). It is more disabling than lethal, with at least 30% of survivors 
making an incomplete recovery and a further 20% requiring assistance in activities of 
daily living (Bonita, Solomon & Broad, 1997). Preventive strategies have resulted in a 
decrease in the rate of stroke attack and death but these improvements have been offset 
in part by the growth of an aging population such that by 2020AD stroke is likely to 
maintain its ranking as the second leading cause of global mortality (Thorvaldsen et al, 
1997; Thorvaldsen et aL, 1999). 
The financial burden of stroke is also huge, accounting for more than 4% of 
healthcare costs in developed countries (Isard & Forbes, 1992; Argentine & Prencipe, 
2000). Indirect costs (e.g. loss of productivity) are difficult to calculate, but may greatly 
exceed the direct costs (de Freitas & Bogousslavsky，2001). 
There has been a decline in the incidence of stroke during the last decades, but 
recent studies suggest that the incidence is no longer declining (Brown et al, 2000) and 
may in fact be increasing. Moreover, ageing of the population may soon result in an 
increase in the absolute number of strokes (de Freitas & Bogousslavsky, 2001). Stroke 
can occur at any age, from newborn babies to octogenarians, but the incidence of 
strokes rises rapidly with age (Rose & Capildeo, 1981), and the risk doubles with each 
decade after age 35. In addition, although important advances in therapeutic 
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approaches, such as thrombolysis, have been made, treatment for stroke is still far from 
satisfactory (de Freitas & Bogousslavsky, 2001). 
What is a Stroke? 
Stroke is often considered to signify paralysis of one half of the body 
(hemiplegia) but in fact the pattern of disability following a stroke is extremely variable 
(Rose & Capildeo, 1981). Rose and Capildeo have made the definition of stroke as: 
A stroke is a sudden (acute) disturbance of brain (cerebral) function of vascular 
origin causing disability lasting more than, or death within, 24 hours. 
'Acute' means that the onset or beginning of the illness is sudden but this does 
not mean within seconds or minutes, but perhaps hours rather than days. 'Disturbance 
of cerebal function' means brain damage, whilst 'vascular origin' means a disorder 
affecting the vessels which supply blood to the brain as opposed to a tumour, which 
could produce a similar disability. The 24-hour limit requirement is because if the 
disability lasts shorter than this, it is given the name ‘transient ischaemic attack' (TIA). 
TIA may not be associated with any obvious structural damage. There is an overlap 
between the brain changes occurring in stroke and TIA and this depends on a number of 
factors, for example the state of the other, non-damaged blood vessels supplying the 
brain and whether they can take over the circulation of the damaged vessels. The 
differentiation of TIA from stroke is made on grounds of the description and duration of 
the illness. The distinction is important because the treatment of the two conditions is 
different: for TIA it is aimed towards the prevention of a more permanent (completed) 
stroke, whilst in the latter, treatment aims at lessening the degree of brain damage. 
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The medical term for stroke is 'cerebrovascular accident' (CVA), but there may 
be confusion when the patient is described as having a 'left CVA，or a 'right CVA’ 
because one side of the brain usually governs the opposite part of the body. It is not 
clear whether the doctor means that the patient with a ‘left CVA' has an abnormality of 
the left side of the brain (left cerebral hemisphere) which will cause a right-sided 
paralysis (hemiplegia), or whether the term is describing a left hemiplegia, which would 
mean that the cause of the stroke was in the right hemisphere. As a result, a more 
general name 'cerebrovascular disease' is used to cover a wide variety of conditions, 
including stroke. 
In general, strokes are divided into two main types: cerebral infarction (or 
ischaemia) and cerebral haemorrhage (Rose & Capildeo，1981), based on the 
mechanisms of the cause (Sharief & Anand, 1997). Of the 2 main types of stroke, 
infarction occurs 80 - 85% of the time (Morris 2002). However, haemorrhagic strokes 
tend to be more serious than ischaemic/infarct strokes, with death occurring in 30 -
50% of people. Figure 1 shows the classification of stroke based on the data from the 
The National Institute of Neurological Disorders and Stroke (NINDS) Stroke Data 
Bank. 
• Cerebral infarction 
The term includes the older terms of ‘cerebral thrombosis' and ‘cerebral 
embolus'. It means that part of the brain is damaged due to lack of blood because the 
vessel feeding the area is blocked. It was recently recognized that the 'blocks' are due 
to the hardening of the arteries in the neck (arteriosclerosis). If the blood supply is not 
restored quickly the affected area of brain tissue dies (becomes ‘infarcted’). Thus 
cerebral infarction was defined medically as ‘an area of brain in which the blood flow 
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has fallen below the critical level necessary to maintain the tissue viability' (Rose & 
Capildeo, 1981). 
• Cerebral haemorrhage 
Cerebral haemorrhage means a bleeding into the brain and is due to the bursting 
of either a blood vessel or an aneurysm (Rose & Capildeo, 1981). An aneurysm is a 
weak spot in the wall of an artery, which balloons out because of the pressure of the 
blood circulating inside the affected artery. The larger the aneurysm, the more likely it 
is to burst. It is unclear why people develop aneurysms, but genes may play a role， 
since aneurysms run in certain families (A.D.A.M., 2002). 
The brain is very sensitive to bleeding and damage can occur very rapidly, 
either because of the presence of the blood itself or the increased pressure. If a lot of 
blood leaks out, it can cause a build-up of pressure in the brain because the brain is 
enclosed in the skull. There is no room for it to expand, and it can compress and kill 
important areas of the brain (Morris, 2002). 
Bleeding irritates the brain tissue, causing swelling (cerebral oedema). The 
surrounding tissues of the brain resist the expansion of the bleeding, which is finally 
contained by forming a mass (haematoma). Both oedema and haematoma will 
compress and displace normal brain tissues (A.D.A.M., 2002). 
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Figure 1. Diagram showing the classification of stroke based on data from 
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The Causes 
Of all 
causes, atheroma is by far the most important especially in the infarction 
type of stroke (Sharief & Anand，1997). As we get older, everyone develops hardening 
of the arteries, often likened to the 'flir' in a kettle or a lead pipe. This 'furring' process 
is due to the development of atheroma, which literally means porridge, and refers to the 
gruel-like properties of the 'fur'. This process is referred to as atheriosclerosis and can 
lead to almost complete blockage (occlusion) of the blood vessel. Atheroma differs 
from the ‘for’ in the kettle or lead pipe in that it cannot be scraped off since it is part of 
the vessel wall (Rose & Capildeo, 1981). A newborn infant has no arterial atheroma 
but, as early as the age of six months, minimal atheroma may already be present. The 
development of atheroma is related to the development of high blood pressure 
(hypertension) but which comes first is uncertain. Many things including high 
cholesterol and high blood pressure cause arteriosclerosis. On the other hand, some 
families have been described who have an inherited lipid (e.g. cholesterol) abnormality 
and develop widespread atheroma at an early age without the development of 
hypertension (Rose & Capildeo, 1981). Ischaemic strokes may also be casued by small 
blood clots or emboli that go through the bloodstream and then get clogged in an artery 
when the artery narrows. These clots can come from pieces of atheroma in the bigger 
arteries that break off or from the heart (Morris, 2002). 
The relationship between atheroma and hypertension can be likened to the 
'chicken and egg，argument, since the presence of hypertension will predispose to 
arteriosclerosis and vice versa. The patients at risk from cerebral haemorrhage often 
have an accelerated form of hypertension, particularly if poorly controlled by treatment 
(Rose & Capildeo, 1981). 
I M l l f l l l W I i l l — 
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Pathophysiology 
When the blood supply to a part of the brain is cut off or greatly decreased, a 
stroke occurs. If the blood supply is cut off for several hours or more, the brain cells, 
without enough blood supply, will die (Morris, 2002). Under normal circumstances the 
adult human brain is entirely dependent on the oxidation of glucose to generate high-
energy phosphate compounds to meet its energy needs. Brain injury is a dynamic 
process that depends on both the severity of ischaemia and its duration (Kasner & 
Grotta, 1997). Reversible alteration in cell function is due to decreased blood flow and 
consequent lack of oxygen occurs in ischaemia. Irreversible alteration is due to 
infarction. After occlusion and deprivation of cerebral blood flow, an ischaemic 
cascade leads ultimately to neuronal dysfunction and death, including the following 
steps (Sharief & Anand, 1997): 
1. decreased cerebral blood flow and cerebral oxygen and glucose consumption in 
the centre of the ischaemic area. These functions are less impaired at the 
periphery of the ischaemic area (penumbra). Obstruction of a blood vessel 
creates a central area of irreversible infarction and a surrounding area of 
potential reversible ‘ischaemic penumbra' which is fundamentally salvageable 
and is therefore the ultimate target of therapy for acute stroke (Kasner & Grotta, 
1997). 
2. impairment of local autoregulatory mechanisms, and initiation of anaerobic 
glycolysis as oxygen and glucose supply decrease. Tissue lactate increases, pH 
decrease. 
3. failure of mitochondrial function and inefficient ATP generation as substrate 
depletion continues. This is associated with leakage of K+ from cells, and 
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intracellular accumulation of Na+, CI", Ca^^ and free fatty acids. The net effect is 
neuronal depolarization, loss of the transmembrane potential, and impairment of 
ATP-dependent neurotransmitter reuptake. 
4. release of excitatory neurotransmitters such as glutamate, which may be 
neurotoxic via activation of N-methyl-D-aspartate receptors, causing increased 
permeability to Na+, cellular swelling and lysis, and massive influx of Ca^^ into 
postsynaptic neurons. 
5. increased intracellular Ca^^ activates enzymes (proteases and phospholipases) 
and generates oxygen free radicals and nitric oxide. These changes lead to 
membrane, mitochondrial and microtubular damage and eventual cell 
destruction. 
During the hours to days after a stroke, the ischaemic territory activates specific 
genes. Formation of cytokines and cell adhesion molecules stimulates local 
inflammation and may further impair blood flow in the microcirculation. Finally 
apoptotic gene activation may promote programmed cell death in the population of 
surviving neurons. Without timely intervention, the entire ischaemic penumbra 
eventually succumbs to these progressive insults and becomes confluent with the infarct 
core (Kasner & Grotta, 1997). 
Diagnosis and Tests 
In diagnosing a stroke, knowing how the symptoms developed is important. The 
symptoms may be severe at the beginning of the stroke, or symptoms may progress or 
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fluctuate for the first day or two (stroke in evolution). Once there is no further 
deterioration, the stroke is considered a complete stroke (A.D.A.M., 2002). 
Examination wi l l look for specific neurological, motor, and sensory deficits, 
because these often correspond closely to the location of the injury to the brain. An 
examination may show changes in vision or visual fields, abnormal reflexes, abnormal 
eye movements, muscle weakness, decreased sensation, and other changes (A.D.A.M., 
2002). 
Tests may determine the location and cause of the stroke and rule out other 
disorders that can cause similar symptoms to stroke. Some common tests are (Rose & 
Capildeo, 1981; A.D.A.M., 2002; Morris, 2002): 
o Computerized tomography (CT) : the principle is that different tissues absorb 
electrons or X-rays to different degrees i.e. different absorption coefficient. 
Because of this, tumour tissue, haemorrhage and infarction can be differentiated 
since each has a different absorption coefficient. It is necessary to exclude the 
presence of haemorrhage in the evaluation of candidates for thrombolytic 
treatment (Linfante, Llinas & Caplan, 1999). The position of the lesion can also 
be shown. Head CT scanning involves taking serial sections (tomography) 
through the brain and measuring the absorption coefficients of the different 
tissues in each ‘slice’, 
o Magnetic resonance imaging (MRI) 
o Electrocardiogram (ECG) : is a measure of the electrical activity of the heart 
and may be used to diagnose underlying heart disorders, 




o Carotid duplex (ultrasound) : may be used i f the cause i f suspected to be 
carotid artery stenosis. 
0 Cerebral (head) arteriography : may be used i f a disorder involving the blood 
vessels is suspected. 
o Routine blood tests : may be used to exclude immune conditions or abnormal 
clotting of the blood that can lead to thrombus formation. However, there is no 
specific blood test available yet for detecting stroke. 
Assessments and Prognosis 
In order to measure the severity of stroke, to quantify the neurological deficit, 
and to predict the immediate and long-term outcome, a number of ‘standardized’ 
disability rating scales were developed. Common scales and assessment tools are 
summarized in Box 1. In this thesis, the Cincinnatic Stroke Scale and LAPSS are used 
because they are used for prehospital and early triage assessment. The GCS and NIHSS 
are the mostly widely accepted, validated and quoted scales. 
Muir et al (Muir et al., 1996) have made a summary on the development of the 
stroke scales: 
Stroke scales exist principally as a result of clinical trials, and their existence 
reflects the heterogeneity of stroke patients and attendant difficulties in reliably 
assessing outcome with respect to disability or neurological deficit. Since the 
introduction of the Mathew scale in 1972 (Mathew et al., 1972), there has been a 
steadily increasing number of scales that seek to quantify neurological impairment. 
These impairment scales involve scoring various modalities of neurological function for 
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an individual and then summing the scores to provide an index of neurological status. 
These scales were developed for a variety of reasons, including monitoring neurological 
status for deterioration and adjusting final outcome for initial severity of stroke in 
clinical trials. Although the purpose of many of these scales has not been explicit, their 
primary uses have been (1) to compare the baseline stroke severity of patient groups and 
(2) to quantify neurological recovery over time. In effect, impairment scales have often 
been used to predict outcome despite not having been designed for this purpose. 
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Box 1. Scales and clinical assessment tools for stroke (Edwards, 2003). 
Prehospital Stroke Assessment Tools 
o Cincinnati Stroke Scale 
o Los Angeles Prehospital Stroke Screen (LAPSS) 
o Acute Assessment Scales 
0 Canadian Neurological Scale (CNS) 
o Glasgow Coma Scale (GCS) 
o Hempispheric Stroke Scale 
o Hunt & Hess Scale 
o Mathew Stroke Scale 
o Mini-Mental State Examination (MMSE) 
o N IH Stroke Scale (NIHSS) 
o Orgogozo Stroke Scale 
o Oxfordshire Community Stroke Project Classification (Bamford) 
o Scandinavian Stroke Scale 
Functional Assessment 
o Berg Balance Scale 
o Modified Rankin Scale 
o Stroke Impact Scale (SIS) 
o Stroke Specific Quality of Life Measure (SS-QOL) 
Outcome Assessment 
o American Heart Association Stroke Outcome Classification (AHA SOC) 
o Barthel Index 
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O Functional Independence Measurement (FIM^^) 
o Glasgow Outcome Scale (GOS) 
Biochemical Markers 
Modem neuroradiological imaging techniques such as CT, MRI and ultrasound 
help clinicians identify the location and volume of an infarct and thus plan treatment. 
However, repeating neuroradiological imaging - usually daily - is impractical (Missler 
et al., 1997). Several monitoring techniques have been developed based on measuring 
levels of various proteins in blood samples and cerebrospinal fluid (CSF), including S-
100 protein, neuron-specific enolase (NSE), myelin basic protein and fibrillary acidic 
protein (Missler et al, 1997). Among these markers, S-100 protein and NSE seems to 
exhibit much correlation with clinical outcomes. They are considered specific 
neurobiochemical markers of brain damage due to stroke (Butterworth et al., 1996; 
Cunningham et al., 1996; Abraha et al., 1997; Buttner et al., 1997), traumatic brain 
injury (Ingebrigtsen, Romner & Tmmpy, 1997; Woertgen et al., 1997; Herrmann et al., 
1999) or cardiac surgery (Aberg, 1995; Blomquist et al., 1997; Rosen et al., 1998). 
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CHAPTER 4 AIMS OF STUDY 
This thesis was planned to evaluate the clinical value of circulating cell-free 
DNA in risk-stratification in patients suffering from mechanical trauma and acute 
stroke. Trauma and stroke are common problems in emergency medicine, and both 
involve tissue injury. The identification of early predictors that help detect patients at 
high risk of developing complications is important, because it is generally believed that 
the earlier the identification, the greater the chances of reducing mortality and 
morbidity. 
The existence of cell-free DNA in the circulation under both normal and 
pathological conditions has been well recognized in the literature of oncology and 
obstetrics, yet its prognostic use in tissue injury is scarcely investigated. As cell death 
is widely proposed to play a significant role in producing the cell-free DNA in the 
blood, it is worthwhile studying the concentration patterns and the role of this DNA 
early after tissue injury in human subjects. The aims are summarized as follows: 
Chapter 6: 
To validate the previous finding of the effect of mechanical trauma on the body 
to the early elevation of circulating cell-free DNA, and the relationship between the 
aberrant concentrations, anatomical injury, OF and MODS development, as well as 
mortality. The effects of anticoagulant and filtration of plasma on the circulating DNA 
concentration have also been examined. 
48 
^ Aim of Study 
• . ... 
Chapter 7: 
To investigate whether early serial and daily temporal changes in the plasma 
cell-free DNA differ between different injury severity and whether different patterns 
emerge between those patients who progress and those who do not progress to develop 
organ failure. 
Chapter 8: 
To investigate and evaluate the prognostic use of plasma cell-free DNA in adult 
patients suffering from acute stroke. Stroke is a type of brain tissue injury which occur 
mainly in elderly people although there is a tendency of happening in younger adults. 
The early plasma cell-free DNA concentration is compared with the outcomes 
(mortality and morbidity) at discharge as well as in 6 months. 
Chapter 9: 
To investigate the daily sequential changes in the plasma DNA concentrations in 
stroke patients. 
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SECTION 2: 
MATERIALS AND METHODS 
The materials and methods used for the quantitation of cell-free DNA in plasma 
samples were the same throughout this thesis. The materials required, principles and 
procedures are summarized in this chapter. 
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CHAPTER 5 METHODS OF MEASURING CELL-
FREE CIRCULATING DNA IN 
PLASMA 
MATEMALS 
DNA Extraction from the Plasma Samples 
The concentration of cell-free DNA present in plasma or serum is very low, 
complexed with cellular proteins and masked by numerous proteins in the plasma and 
serum. Such cell-free DNA therefore, needs to be extracted, purified and concentrated 
before the RTQ-PCR measurement. 
DNA extraction kit 
The QIAamp® DNA Mini Kit (Qiagen GmbH, Hilden, Germany) is designed 
for genomic DNA purification from tissue, blood and body fluids. The “Blood and 
Body Fluid Spin Protocol" was adopted in our studies to extract DNA from plasma 
samples. Spin columns, protease, buffers and collection tubes were included, and each 
kit is enough for 250 extractions. 
Absolute ethanol 
Absolute ethanol (Merck KgaA, Darmstadt, Germany) was used for DNA 
precipitation after protease digestion during the extraction process according to the 
"Blood and Body Fluid Spin Protocol". 
51 
______ Materials and Methods 
Real-time Quantitative PGR (RTQ-PCR) 
TaqMan 糊PCJt Reagent Kit 
The kits were purchased from Applied Biosystems, CA, USA, which contain 
following reagents necessary for the P-globin assays: 
0 1 OX TaqMan™ Buffer A 
o 25mM MgCb Solution 
o dATP, dCTP, dGTP，dUTP 
o AmpliTaq™ Gold (5 U / | L I L ) 
o AmpErase® U N G (1 U / | L I L ) 
Primers 
Beta-globin forward and reverse primer pairs were synthesized by GENSET 
Singapore Biotech, Singapore. The sequences of the P-globin primer pair were p-
globin -354F (5,-GTG CAC CTG ACT CCT GAG GAG A-3') and P-globin -455R 
(5'CCT TGA TAG CAA CCT GCC CAG-3'). 
Probe 
The dual-labelled fluorescent TaqMan probe was synthesized by GENSET 
Singapore Biotech, Singapore. The sequence was P-globin -402T[5‘-(VIC)AAG GTG 
AAC GTG GAT GAA GTT GGT GG (TAMRA)-3' ] . 
Primers and probe were designed using the Primer Express software (Applied 
Biosystems version 2.0), while the P-globin sequence was obtained from the GenBank 
Sequence Database. 
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PCR plate and cap 
MicroAmp® Optical 96-Well Reaction Plate and MicroAmp® Optical 8-strip 
Caps were purchased from Applied Biosystems. 
PCR detector 
RTQ-PCR was carried out in an automatic AB I PRISM 7700 Sequence 
Detector, which was purchased from Applied Biosystems. 
i i W l i l i f — M W P P ^ P P — — ^ ― ^ ― — S ! 
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M E T M O I M 
DNA Extraction from the Plasma Samples 
DNA in the plasma was extracted using the “Blood and Body Fluid Spin 
Protocol" of the QIAamp DNA Mini Kit. It is a column-based extraction method, 
which minimizes cross-contamination. The protocol requires no phenol/chloroform 
extraction or alcohol precipitation. A l l reagents (except ethanol) and columns were 
included in the kit. The extracted DNA was claimed to be free of protein, nucleases, 
and other contaminants or inhibitors. The extraction was reported to be very useful in 
the study of plasma DNA (Lo et al., 1998a; Wu et aL, 2002). 
The whole procedure is illustrated in Figure 2. Two-hundred microlitres plasma 
per sample was used for each extraction. Briefly, plasma was mixed vigorously with 
20|jL protease and 2QQ\xL buffer. Two-hundred microlitres cold absolute ethanol was 
added after 15 minutes incubation at 56°C and mixed vigorously. The 620|LIL mixtures 
were then transferred into a spin column with silica-gel membrane. DNA was allowed 
to adsorb on the membrane with a brief period of centrifugation (13000 x g for 1 
minute, centrifugation 1). The filtrate was then discarded. The membrane with DNA 
adsorbed was washed twice with two different washing buffers (AWl and AW2) 
provided, at 13000 x g for 1 minute (centrifugation 2) and 3 minutes (centrifugation 3) 
respectively. The purified DNA on the membrane was finally eluted in 50|LIL sterile 
water, by centrifugation at 13000 x g for 1 minute (centrifugation 4). The extracted 
DNA was stored under -20°C pending further analysis. 
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Figure 2. Spin procedure for the extraction of DNA from plasma 
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Real-time Quantitative PCR 
Principle 
The RTQ-PCR system used for the studies in this thesis was described by Heid 
et al in 1996 (Heid et al., 1996), using a fluorescent TaqMan assay and a sequence 
detector capable of measuring fluorescent in real time. The TaqMan assay consists of a 
dual-labelled fluorogenic hybridization probe, an oligonucleotide with a 5'- reporter dye 
(e.g. VIC) and a 3’- quencher dye such as TAMRA, anneals to a site of the target DNA 
sequence (the probe is complementary to that part of the sequence) between the forward 
and reverse primers The probe has a higher melting temperature (Tm) then the primers, 
and during the extension phase, the probe must be 100% hybridized for the success of 
the assay. When the probe is intact, the reporter fluorescence is suppressed by a 
quencher dye. During the PCR process, and i f the target of interest is present, the 
reporter dye wi l l be cleaved by the 5'-3' nuclease activity of the Taq DNA polymerase 
when the upstream primer is extended to the site where the probe is annealed. 
Fluorescence wi l l then be emitted. Figure 3 illustrates the process. Additional reporter 
dyes are cleaved from probes when more PCR cycles proceed, resulting in an increase 
in fluorescence intensity. The fluorescence signal is measured during the whole 
process, and is monitored by the sequence detector. 
The RTQ-PCR was carried out in an ABI PRISM 7700 Sequence Detector 
(Applied Biosystems), a combination of thermal cycler and fluorescence detector to 
monitor the progress of each PCR reaction. The system consists of a 96-well cycler 
connected to a laser and charge-coupled device (CCD) or optical fibre inserted through 
a lens is positioned over each well, and laser light is directed through the fibre to excite 
the PCR solution (Grove, 1999). Emissions are sent through the fibre to the CCD 
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camera, where they are analyzed by the software's algorithms subsequently sent to the 
computer (Grove, 1999). 
The sensitivity of detection allows acquisition of data when PCR amplification 
is still in the exponential phase. This is determined by identifying the cycle number at 
which the reporter dye emission intensities rise above background noise; this cycle 
number is called the threshold cycle (Cj). C j is defined as the fractional cycle number 
at which the reporter fluorescence signal generated exceeds a threshold above the 
baseline signal, and is determined at the exponential phase of the reaction and is more 
reliable than end-point measurements of accumulated PCR products used by many 
traditional PCR methods. The C j is inversely proportional to the copy number of the 
target template, the higher the template concentration, the lower the C t measured 
(Grove, 1999). A plot of the log of initial target copy number for a set of standards 
versus C t is a straight line (Higuchi et al., 1993). Quantitation of the amount of DNA 
in sample is accomplished by measuring C t and using the standard curve to determine 
starting copy number. 
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POLYMERIZATION 
龜 R« bepobter 
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— — 3: (Q), are attached to the 
mnm^ probes. 
PRI_R 
Smm D i s p l a o e m e n t i承 ^ 
t t 
y When both dyes are attached 
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S* 3' emission is quenched. 
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Figure 3. Diagram showing the incorporation of a TaqMan 
fluorogenic probe and the release of fluorescent dye during the 
subsequent PCR amplification (Applied Biosystems，2000). 
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The P-globin TaqMan Assay 
Cell-free DNA in plasma was measured quantitatively by determining the 
quantity of P-globin gene measured by PCR. P-globin is present in all nucleated cells 
of the body. The assay was established in 1998 (Lo et al., 1998a). The sequences of 
the P-globin primer pair were P-globin -354F (5'-GTG CAC CTG ACT CCT GAG 
GAG A-3，）and P-glohin -455R (5'CCT TGA TAG CAA CCT GCC CAG-3，); and the 
sequence for the dual-labelled fluorescent TaqMan probe was P-globin -402T[5'-
(VIC)AAG GTG AAC GTG GAT GAA GTT GGT GG (TAMRA)-3']. VIC was 
incorporated at the 5’ end of the probe and served as the reporter; while TAMRA was 
the quencher which incorporated at the 3' end. 
The assay was performed on an optical 96-well PCR reaction plate. Each 
reaction well contained components supplied in a TaqMan PCR Core Reagent Kit 
(Applied Biosystem), the primers and probe, and the target DNA sample. A master mix 
(without the target DNA) was usually prepared for all samples (Box 1) and then 
aliquoted into the individual wells of the 96-well plate. Master mix preparation can 
minimize reagent pipetting losses, increase accuracy, and reduce the number of reagent 
transfers. The volume for each reaction well was made up to 45jLiL with sterile and 
double distilled water. Then 5|LIL of each DNA sample was loaded into the wells, 
resulting in a final volume of 50 |JL . N O template controls ( N T C ) and a standard curve 
were run concurrently in every analysis. NTC is the complete reaction mix without 
DNA samples. The standard curve was serially diluted known amount of DNA. Al l 
samples, NTC and standard curve were run in duplicates. The thermal profile is 
outlined in Box 2. The whole process takes about 1 hour 50 minutes. 
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Box 1. Components for the master mix of the P-globin RTQ-PCR assay. 
Component Concentration 
TaqMan buffer A 1 X 
MgCl2 4 m M 
Each dATP, dCTP and dGTP 200 [ iM 
dUTP 400 | iM 
P-globin Forward Primer 300 nM 
P-globin Reverse Primer 300 nM 
P-globin probe 100 nM 
AmpliTaq Gold 1.25U 
AmpErase Uracil N-glycosylase (UNG) 0.5U 
Box 2. Thermal profile for p-globin RTQ-PCR assay 
50°C 2 minutes 
95°C 10 minutes 
95°C 15 seconds 40 
^ cycles 
60°C 1 minutes 」 
Al l data were collected by the Detector and could be analysed by the 
corresponding software (Applied Biosystem). Concentration of DNA in terms of P-
globin, can be calculated by the following equation: 
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Where: 
C = target concentration in plasma (copies/mL) 
Q = target quantity (kilogenome) determined by the 7700 sequence 
detector, themean quantity of each duplicate was used 
V D N A = total volume of DNA obtained after each extraction i.e. SOjiL 
VpcR = volume of DNA solution used for PCR, S^iL 
Vext = volume of plasma used in DNA extraction i.e. 0.2 mL 
The concentration was expressed in "kilogenome-equivalents/L". One genome-
equivalent was defined as the amount of a target sequence contained in a single diploid 
human cell. The RTQ-PCR system was reported to be sensitive enough to detect the 
DNA equivalent from a single target cell; and the coefficient of variation of threshold 
cycle was found to be 1.1% (Lo et al., 1998a). 
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Calibration of the P-globin TaqMan System 
The sensitivity was demonstrated by the standard curve (or calibration curve). 
The standard curve contained 10 serially diluted genomic DNA extracted from the buffy 
coat of healthy human subjects. The concentrations of the standard curve ranged from 
0.78 to 1000 kilogenome-equivalents/L. Each concentration was amplified in duplicate. 
Amplication plot of the standard curve is shown in Figure 4(a). The more dilute 
the starting DNA templates, the more amplification cycles are required to produce 
enough fluorescence to reach the threshold level. Threshold level is where the 
amplification curve of each individual concentration departs from the baseline. 
Therefore the amplication curves observed were shifted to the right as the 
concentrations decreased. 
Figure 4(b) illustrates the standard curve after amplication. The log of the DNA 
concentrations is inversely related to CT. The CT values of the duplicates are very close, 
indicating that the system is accurate and that the handling technique of the researcher is 
acceptable. Concentrations from unknown samples could thus be deduced by 
substituting the Ct values to the standard curve. Every amplification experiment should 
have its own standard curve. 
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Figure 4. The amplication plots and standard curve of the dilutions of 
a known amount of P-globin sequences analysed by RTQ-PCR. 
(a) Amplification plots for reactions with starting P-globin sequences 
concentration ranging from 0.78 to 1000 kilogenome-equivalents/L. Cycle number is 
plotted versus change in normalized reporter signal (ARn). ARn represents the 
normalized reporter signal (Rn) minus the baseline signal calculated during the first 15 
cycles. Two replicates for each concentration were performed, but the data for only one 
is shown here, (b) Standard curve plotting log starting concentration versus threshold 
cycle (CT). CT represents the cycle number at which the fluorescence exceeds a 
threshold limit (typically 10 times standard deviation of the baseline). The data from 
the two replicates at each concentration are plotted. The correlation coefficient of the 
standard curve was 0.98. 
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Contamination Control 
Due to the high sensitivity of RTQ-PCR system, precautions have to be 
followed to avoid contamination. At least five procedures were taken during every 
analysis: (1) The master mixes were prepared in a safety cabinet specific for PCR 
(OMNI PCR Work Station, Aste Environmental System Limited, UK); and the process 
of reagent preparation and DNA sample loading were carried out in an isolated area. 
(2) Aerosol-resistant pipette tips were used throughout the whole process. (3) UNG was 
added in each assay to excise all uracil in carry-over dU-containing PCR products from 
previous PCR amplifications thus preventing subsequent re-amplification of previous 
PCR products (Longo, Beminger & Hartley, 1990). (4) The optical detection system 
itself provided by the 7700 Sequence Detection System requires no reopening of the 
reaction wells after completion of the amplification reactions thereby minimizing the 
possibility of carry-over contamination. (5) Multiple NTCs were run concurrently in 
every assay to double check for any contaminations. 
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SECTION 3 
CELL-FREE CIRCULATING DNA CONCENTRATION AFTER 
TRAUMA 
The chapters (Chapters 6 and 7) in this section investigate the changes of cell-
free circulating DNA concentration in the plasma of patients suffered from mechanical 
trauma. Attempt is made to correlate the aberrant concentrations with the severity of 
injury and the post-traumatic complications. Both early (hourly) and daily changes are 
described. 
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CHAPTER 6 CELL-FREE CIRCULATING DNA 
CONCENTRATION AS A 
PROGNOSTIC MARKER IN PATIENS 
AFTER TRAUMA 
Introduction 
Patients surviving severe trauma frequently suffer from post-traumatic 
complications such as acute lung failure (ALI), acute respiratory dysfunction syndrome 
(ARBS) and multiple organ dysfunction syndrome (MODS) (Neidhardt et al., 1997). In 
spite of the advances in treating many complicated cases, treatment is difficult and the 
mortality rate is high especially when five or more organs fail. Such organ failures 
recover poorly partly due to inadequate knowledge of the pathophysiology as well as an 
inability to make an early diagnosis. Early prediction of outcome therefore is an 
important part of the trauma research. It is important to predict outcomes as early as 
possible after trauma as it may influence treatment and help physicians identify high-
risk patients for intensive care. 
Lo et al first reported a marked elevation of cell-free DNA in the plasma of 
trauma patients (Lo et al., 2000c). The initial idea was prompted by the successful 
detection as well as the diagnostic and prognostic values of cell-free DNA in the plasma 
or serum of cancer patients (Stroun et al., 1989; Anker et al., 1999), pregnant women 
(Lo et al., 1997; Lo et al., 1998a), and organ transplantation recipients (Lo et al., 
1998b). Lo et al believed that DNA may be released into the circulation from damaged 
tissues during trauma. Based on the preliminary results, prediction models for the 
imminent onset of post-traumatic organ failure were then derived using plasma cell-free 
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DNA concentrations, combined with several clinical variables (e.g. aspartate 
transaminase, shock index，maximal abbreviated injury score) (Rainer, 2001). The 
prediction models offered the possibility that OF and MODS may be diagnosed and 
predicted within 4 to 6 hours of the initial injury. Moreover, both sensitivity and 
specificity were improved over previous prediction models. For example, the model 
developed by Sauaia et al (Sauaia et al., 1998) claimed that post-traumatic 
complications could be diagnosed by 12 hours after injury and had a sensitivity of 63% 
and specificity of 84%. 
The preliminary study of Lo et al, however, was a secondary analysis of 
archived heparinized plasma samples for clinical tests other than plasma DNA analysis. 
Some studies had shown that heparin is not an ideal anticoagulant and may affect the 
efficiency of the polymearase chain reaction (PCR), which in turn may affect the 
accuracy of the DNA concentration measurement (Jen, Wu & Sidransky, 2000). 
Therefore ethylenediaminotetraacetic acid (EDTA) was chosen as the anticoagulant for 
plasma collection in nearly all studies in this thesis. However, to prove that the 
elevation of cell-free DNA in the preliminary study was not due to the ‘artifacts’ of 
heparin, paired blood samples using EDTA and heparin as the anticoagulants were 
taken from healthy subjects as well as trauma patients to compare i f there are 
differences between the plasma DNA concentrations from the two anticoagulants used. 
Methods of centrifugation and filtration during plasma preparation may be another 
important clue to the analysis of cell-free DNA (Chiu et al., 2001). Inadequate or 
inappropriate processing may produce residue blood cells in the plasma and wi l l 
subsequently affect the DNA concentration in the plasma. Blood processing protocol 
recommended by Chiu et al (Chiu et al., 2001) was generally adopted in this study. 
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The major objective of this chapter was to investigate prospectively, firstly 
whether on an independent cohort of trauma patients, similar trends and phenomena 
despite different anticoagulants and centrifugation/filtering methods, are reproducible. 
Secondly, to investigate pre-analytical issues such as the effect of anticoagulant, and the 
effect of filtration on trauma plasma samples. 
Methods 
Subjects 
Ethical approval was obtained from the Research Ethics Committee of The 
Chinese University of Hong Kong. Informed consent was sought from the patient or the 
most senior relative present as appropriate. In view of the critical nature of trauma and 
the importance of early markers for both diagnosis and prognosis, the request has been 
made that the essential requirement for prior consent for the emergency department 
research blood sample, which was taken in conjunction with routine admission blood 
samples, be waived. Consent was sought at the earliest possible opportunity. A l l 
samples were discarded and the patients were excluded from the study i f the patient or 
relative subsequently refused consent. 
Patients who sustained an acute traumatic injury and were admitted to the 
resuscitation room at the Emergency Department of the Prince of Wales Hospital 
between July 2000 and December 2002 were recruited with the following criteria: (1) 
Time of injury to admission was less than four hours; (2) age greater than 13; (3) no 
ongoing pregnancy; (4) trauma not due to drowning, hanging, thermal injury, 
hypothermia, and acute drug overdose. Blood samples were taken as soon as possible 
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when patients were admitted. However, for the purpose of this thesis, blood samples 
taken more than four hours to the time of injury were also included. There are two 
major reasons for delayed blood sampling. In some situations, patients were transferred 
from another hospital a few hours after injury, without much clinical intervention. 
Sometimes in cases of severe injuries, the research team had to wait until early 
resuscitations and radiological investigations were done, then blood samplings were 
allowed. 
Basic demographic data (age, sex), time and mode of injury, site and type of 
injury together with subsequent clinical examination data was collected. The history 
taken, routine laboratory results and clinical examination conducted was used to 
determine injury severity and outcomes. 
Injuries detected in the emergency department and on subsequent hospitalization 
were scored using the ISS, a well-established objective anatomical scoring method 
(Baker et al., 1974). The primary clinical outcomes were death and MODS. MODS 
was defined according to Goris et al (Goris et al., 1985). MODS develops after injury 
and data from failing organs/systems were collected 48 hours after injury as any 
abnormality is more likely to be due to the emerging inflammatory process rather than 
initial direct trauma. 
Blood samples from sex and age matched healthy subjects were collected as 
controls. Verbal consent was obtained and each of the control subjects were asked to 
f i l l in a questionnaire to make sure that they did not have diseases and were not taking 
any medications 2 weeks prior to the blood test. 
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End Points 
The study end points were set at the time of discharge or death i f either were 
within 28 days of injury, or at 28 days post-injury i f the patient was still admitted. 
Patients discharged to a chronic care facility were considered discharged but those 
transferred to another hospital after sampling because of a shortage of beds were 
included in the study. 
Blood Sampling and Sample Processing 
To fulf i l the first objective of the study and to evaluate the effects of filtration, 6 
mL peripheral blood was collected from trauma patients into EDTA-containing tubes 
(Vacuette, Greiner, Kresmiinster, Austria) as soon as possible when patients were 
admitted. For the investigation of anticoagulant effect on plasma DNA, an extra 4 mL 
lithium heparinized (Vacuette, Greiner, Kresmiinster, Austria) blood was also collected 
from each patients. 
A l l blood samples were centrifuged at 1600 g for 10 minutes (LabofUge 400R, 
Heraeus, Hanau, Germany), and plasma was carefully removed with great care not to 
disturb the buffy coat layer. Half of the plasma from EDTA was subjected to filtration 
through 0.22}im syringe filters (Millex-GV, Millipore, Bedford, USA); while the rest 
was left unfiltered. It was not always possible to have enough blood for plasma 
filtration, therefore only unfiltered plasma samples were available in some cases. 
Plasma from all heparinized samples was left unfiltered. A l l filtered and unfiltered 
plasma were transferred into clean plain polypropylene microtubes and were stored 
under -80 °C pending DNA quantitation. 
Collection of blood samples from healthy controls followed the same strategy as 
trauma patients and was processed in the same way. 
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Quantitation of DNA in Plasma 
Procedures for DNA extraction and the RTQ-PCR followed that described in 
Chapter 5. 
Statistical Analysis 
Al l clinical and plasma DNA data collected were entered into a Statview 5.0 
database. Descriptive statistics and non-parametric comparison tests were performed 
using Statview® for Windows version 5.0 Statistical Analysis Software (Abacus 
Concepts, SAS Institute, Gary NC, USA). Pairwise comparisons were done using 
SigmaStat (SPSS, Chicago, IL, USA). Receiver operator characteristic (ROC) curve 
analysis was carried out using the MedCalc 5.0 software (Mariakerke, Belgium). 
Results 
A total of 103 patients and 72 controls were recruited. Over 91% of all trauma 
were blunt injuries with mean ISS = 12 (range 1 - 38). Sixty-nine patients were 
categorized as minor/moderate injury (ISS < 15) and 34 patients were severely injured 
(ISS > 16). The majority were male (81%) of age 14 - 82 years (mean = 42.4 years). 
The median time between blood sampling to the time of injury was 70 minutes (range 
10 - 780 minutes). The patient characteristics are summarized in table 1. 
71 
Cell-free DNA Concentration After Trauma 
Chanses in the Cell-free DNA in Plasma Associated with Trauma 
Plasma DNA Concentration after Trauma 
The median plasma DNA concentration from all trauma patients was 6 672 
kilogenome-equivalent/L, which was 10-fold higher than that of controls (640 
kilogenome-equivalent/L). The difference between the two groups was highly 
statistically significant (p < 0.0001; Mann-Whitney test). 
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Table 1. Characteristics of 103 trauma patients. 
Characteristics Patient Number 
Total “ 
Male sex [%] 83 [80 
Age (years) - median [range] 
Male 43 [14-82] 
Female 41 [15-82] 




Mechanism of injury 




Injury Severity Score 
Overall median ISS [range] ' 9 [1-38] 
Minor (ISS < 9) 47 
Moderate (ISS = 9-15) 22 
Severe (ISS > 15) 34 
Anatomic sites of injury (major injury site )^^  
Head and neck 32 
Face 1 
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^Some patients had more than one main injury site. 
Major injury defined as having A IS > 3 in each site. 
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Plasma DNA Concentration and Injury Severity 
Figure 5 shows the plasma DNA concentrations in control, minor/moderate 
(median ISS = 5) and severe (median ISS = 25) subgroups. The respective median 
plasma DNA concentrations were 640, 2 608 and 6 6090 kilogenome-equivalent/L. The 
difference in plasma DNA concentrations between the two trauma subgroups and the 
control group was tested by Kruskal-Wallis test. The difference among the 3 groups 
was highly significant statistically (p < 0.0001). Pairwise multiple comparison using 
the Dunn's Method was also performed to compare differences between the 2 subgroups 
and the 2 subgroups against the controls. Statistical significances were obtained (p < 
0.05) in all pairs. Positive correlations were also found between the ISS groups and 
plasma DNA concentrations using the Kruskal-Wallis Test with (p < 0.0001) and 
without (p < 0.0001) the control group. 
Plasma DNA Concentration and Clinical Outcome 
MODS and mortality were the two major outcomes to be independently 
investigated (Figures 6 and 7). Eleven severely injured patients were diagnosed to have 
MODS. The median plasma DNA concentration in patients with MODS was 57 855 
kilogenome-equivalents/L and 5 990 kilogenome-equivalents/L for those without 
MODS (a 10-fold different). The difference between them was highly significant (p = 
0.0025, Mann-Whitney test). 
Six severely injured patients died within the study period (i.e. within 28 days 
from the day of injury). Patients who died had a median plasma DNA concentration of 
109 260 kilogenome-equivalents/L, 17-fold higher than the survivors (6 442 
kilogenome-equivalents/L). The difference between them was also highly significant 
by using Mann-Whitney Rank Sum Test (p = 0.013). 
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Figure 5. Plasma DNA concentration and the injury severity (ISS). 
Box plots showing the effects of injury severity on the plasma DNA 
concentration in terms of y^-globin sequence (kilogenome-equivalents/mL). Controls 
and the two trauma subgroups denoted by "Minor/Moderate" (ISS 1 — 14) and “Severe” 
(ISS > 1 5 ) are compared. Y-axis represents plasma DNA concentrations. The upper 
and lower limits of the boxes, and the lines across the boxes, indicate the 
percentiles and the medians, respectively. The upper and lower horizontal bars indicate 
the 90仇 and percentiles, respectively. Outliers are illustrated as black dots. 
Significant difference was found among the three groups statistically (p < 0.0001, 
Kruskal-Wallis test). 
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Figure 6. Plasma DNA concentration and the development of MODS. 
Box plots illustrating the plasma DNA (/?-globin) concentrations in controls and 
trauma patients who developed MODS or did not develop MODS. "MODS absent" 
represents patients who did not develop MODS; and “MODS present，，represents 
patients who developed MODS. Y-axis represents plasma DNA concentrations. The 
upper and lower limits of the boxes, and the lines across the boxes, indicate the 75出,25^ 
percentiles and the medians, respectively. The upper and lower horizontal bars indicate 
the 90th and 10^ percentiles, respectively. Outliers are illustrated as black dots. The 
difference between "MODS absent" and "MODS present" was highly significant (p = 
0.0025, Mann-Whitney Rank Sum Test). 
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Figure 7. Plasma DNA concentration and mortality. 
Box plots illustrating the plasma DNA (y^-globin) concentrations in controls and 
patients suffering from trauma who (1) survived and (2) died. “Trauma, alive" denotes 
the survivors, whilst “Trauma, died" denotes those who died. The y-axis represents 
plasma DNA concentrations. The upper and lower limits of the boxes, and the line 
across the boxes, indicate the 25^ percentiles and the medians, respectively. The 
upper and lower horizontal bars indicate the and percentiles, respectively. 
Outliers are illustrated as black dots. Statistical significant difference was found 
between the patients died and those who stayed alive (p = 0.013, Mann-Whitney test). 
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ROC Curve Analysis 
The ROC curves for plasma DNA concentrations on MODS and death are 
shown in figure 8. The areas under the ROC cures, sensitivities and specificities of 
plasma D N A concentration for the prediction of MODS and death are summarized in 
Table 2. 
Table 2. The areas under the ROC curves, the sensitivities and specificities 
of plasma DNA concentrations (kilogenome-equivalents/L) for the 
predictions of MODS and death. 
Area under ROC curve Sensitivity Specificity 
(SE; 95% CI) (95% CI) (95% CI) 
0.780 81.8 67.4 
Mori<s 
(0.085; 0.687 - 0.855) (48.2 — 97.2) (56.8 — 76.8) 
Cut off: Plasma DNA concentration > 15 000 
kilogenome-equivalents/L 
0.804 83.3 78.4 
Death (0.110； 0.714 - 0.876) (36.1 - 97.2) (68.8 - 86.1) 
Cut off: Plasma DNA concentration > 50 000 
kilogenome-equivalents/L 
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Figure 8. ROC curve analysis of plasma DNA concentration for 
MODS and mortality. 
The ROC curve analysis of plasma DNA concentration for prediction of (a) 
MODS, and (b) death. The values indicated on both x- and y-axes are expressed in 
percentages. Area under the ROC curves are 0.780 in (a) and 0.800 in (b). 
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The Effect of Anticoagulant on Plasma DNA Concentration 
Figure 9 showed the individual differences between the plasma DNA 
concentrations derived from EDTA and heparin plasma of the same trauma patient or 
control subject. 
Thirty-seven trauma patients and 10 healthy controls paired EDTA and heparin 
plasma samples were collected. In trauma samples, the median plasma DNA 
concentrations from EDTA and heparin were 6 153 and 5 308 kilogenome-
equivalents/L respectively, (figure 5a; p = 0.73 Wilcoxon Signed Rank Test). 
No statistical significance was also observed in the 10 paired control samples 
(figure 5b; p = 0.96; Wilcoxon Signed Rank Test), with median plasma DNA 
concentrations 588 and 537 kilogenome-equivalents/L respectively for EDTA and 
heparin samples. 
The Effect of Filtration on Plasma DNA Concentration 
Twenty-seven trauma and 10 control plasma samples were collected in the 
study. Figure 10 shows the individual plasma DNA concentrations differences between 
the paired filtered and non-filtered samples. There was no statistical significance 
between filtered and non-filtered samples in both trauma (median plasma DNA 
concentration = 7 874 vs 8 793 kilogenome-equivalents/L; p = 0.76, Wilcoxon Signed 
Rank Test) and control group (median plasma DNA concentration = 680 vs 865 
kilogenome-equivalents/L; p = 0.17, Wilcoxon Signed Rank Test). 
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Figure 9. Effects of anticoagulation on the plasma DNA 
concentrations. 
The graphs show the paired individual variations on plasma DNA concentrations 
iy-axis) between the two anticoagulants (EDTA and heparin) used (x-axis). No 
statistical significances were observed in (a) 37 paired trauma plasma samples (p = 0.73 
Wilcoxon Signed Rank Test) and (b) 10 paired plasmas samples from healthy subjects 
(p = 0.96 Wilcoxon Signed Rank Test). 
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Figure 10. Effect of plasma filtration on the plasma DNA 
concentrations. 
Plasma was either filtered through 0.22\im syringe filter (denoted "Filtered") or 
left unfiltered (denoted "Non-filtered"). No statistical significances of plasma DNA 
concentration (y-axis) were observed between (a) 27 paired trauma plasma samples (p = 
0.76 Wilcoxon Signed Rank Test) and (b) 10 paired plasmas samples from healthy 
subjects (p = 0.17 Wilcoxon Signed Rank Test). 
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Discussion 
\ 
A significant elevation of cell-free DNA in plasma of trauma patients was first 
reported in 2000 (Lo et al., 2000c). The elevation correlated well with injury severity 
and post-traumatic complications, and was proposed to be a potential useful prognostic 
tool for stratification of trauma patients. The present study, on the other hand, 
represents an independent validation of the previous study. Ideally, findings should be 
derived in one group of patients and validated in another (Schuster, 1992; Cowen & 
Kelley, 1994) before the findings are accepted. The present results clearly demonstrated 
that cell-free DNA in plasma was elevated after trauma. Moreover, the elevated 
concentration was also positively correlated with injury severity, death and MODS. A l l 
these observations confirm the previous findings. (Lo et al., 2000c). 
Although similar trends of plasma DNA concentrations after trauma were 
obtained, the absolute DNA concentrations measured in present study were much 
lowered than the previous study. This could not be explained by the use of different 
anticoagulants (EDTA and heparin) because it was proved in the present study that 
plasma DNA concentrations are not apparently affected by the exact type of 
anticoagulant. The median plasma DNA concentration of the healthy controls in 
present study was 640 kilogenome-equivalents/L whereas the value reported in previous 
study was 3 154 kilogenome-equivalents/L. There are several possible explanations: (1) 
the whole process was done by a different researcher, and there might have individual 
variations. (2) The performance efficiency of the ABI PRISM 7700 Sequence Detector. 
The present study was done two years later than the previous one, where the original 
efficiency of the PGR detector might have changed. (3) The shift of standard curve is a 
more probable explanation. At present it is not possible to synthesize a synthetic 
oligonucleotide of over 100 base-pairs (the size of the beta-globin amplicon is between 
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100 - 200 base-pairs). Standard samples are generally prepared from the buffy coat of 
healthy subjects and may be subject of individual variations. Frequent freeze-thrawing 
of standard samples might also create discrepancy to the absolute values. Therefore, 
alternative ways , for example, Multiple of Median (MOM) to present the quantitative 
data other than using the absolute values. 
The origin and mechanism underlying the liberation of cell-free DNA into the 
circulation are not fully understood. One possibility is cell death, either necrosis or 
apoptosis. In regard to trauma, since plasma DNA concentrations were positively 
correlated with injury severity, it is logical to postulate that the 'extra' DNA was come 
from injured tissues or cells, as injury severity is a direct reflection of anatomical 
injuries. The exact mechanisms underlying the appearance of circulating cell-free 
DNA increase after trauma are also unclear although both apoptosis and necrosis are 
possible. Much work has been done using cancer as a model (Giacona et al., 1998; 
Stroun et al., 2001; Jahr et al., 2001), and both phenomena have been observed. In 
cancer patients, cell-free DNA exists as fragments thus providing both qualitative and 
quantitative evidence that it originates from apoptotic or necrotic cells (Jahr et al., 
2001). These fragments are approximately 100-200 base-pairs in size and the 
electrophoretic patterns were more prominent in plasma of cancer patients than in the 
plasma of healthy subjects (Giacona et al., 1998; Wu et al., 2002). Active release of 
DNA into the bloodstream is another possible source of cell-free DNA (Stroun et al., 
2000; Stroun et al., 2001). The very early, high levels of plasma DNA observed in 
severely or multiply injured patients suggests that extracellular DNA may originate 
from damaged tissues i.e. necrosis. Apoptosis is a complex process highly regulated by 
many genes (Williams & Smith, 1993) and may take several hours to develop (Vermes 
et al., 1995). The high levels of plasma DNA detected in our studies occur as early as 
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10 minutes after trauma, in which case apoptosis is unlikely to be the main precipitating 
cause although accelerated or large-scale apoptosis may contribute to persistently 
elevated later levels. Other trauma studies have also reported that apoptosis at least in 
polymorphonuclear leucocytes is suppressed in patients with post-traumatic 
complications such as the Adult Respiratory Dysfunction Syndrome and MODS (Ogura 
et al., 1999; Nolan et al., 2000). This suppression may be due to the presence of high 
concentrations of inflammatory mediators in the circulation. Impaired clearance is 
another possible reason for the elevation in cell-free DNA. In healthy pregnant 
mothers, plasma DNA after delivery has an extremely short half-life in the circulation 
(Lo et al., 1999f). However after trauma, organs responsible for elimination might be 
damaged as a consequence of ongoing systemic inflammation. Furthermore, the role of 
high concentration of cell-free DNA in the plasma after trauma is unclear. Whether it is 
merely the consequences of increased tissue injuries or wi l l these cell-free DNA 
involved in the pathophysiological changes leading to MODS need to be further 
elucidated. Quantitative and quanlitative analysis of cell-free DNA may help researcher 
identify which organs are damaged and the degree of severity of injury. 
Despite extensive clinical studies of circulating cell-free DNA in the past 
decade, many questions remain regarding preanalytical issues. Blood collection, 
storage, sample processing, DNA extraction and methods of analysis may all affect the 
final quantitative results. One of the fundamental factors is the existing forms of DNA 
in the plasma or serum. Chiu et al have reviewed and compared several strategies to 
collect plasma from the whole blood of pregnant women (Chiu et al., 2001). They 
found that plasma harvested from inappropriate processing such as Percoll gradient 
separation, and low centrifugation force (e.g. 800g), would lead to significant increase 
in plasma DNA concentration when compared to samples obtained from centrifugation 
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at 1 600g followed by micro-centrifugation at 13 OOOg or filtration through 0.22|Lim 
filters. This provided evidence that residual cells in plasma would be introduced from 
inappropriate blood processing protocol in turn affected the subsequent plasma DNA 
measurements. Hence, at the beginning of the present study, a stringent protocol was 
designed: centrifugation at 1 600g followed by filtration through 0.22|Lim syringe filters. 
However, in some cases, less than ImL of blood could be taken from patients, which the 
subsequent plasma volume was hardly enough for filtration. Unfiltered plasma was also 
stored in order to enlarge the sample size. In order to clarify whether unfiltered plasma 
should be used for the study, a small experiment was carried out to elucidate the effect 
of filtration on plasma DNA concentration from trauma patients, as well as healthy 
controls. Paired filtered and nonfiltered plasma samples from the same patient or 
healthy subject were collected. The results indicated that there was no significant 
difference (p = 0.6, Wilcoxon test) between filtered and non-filtered pairs among both 
trauma and healthy groups. The centrifugation at 1 600g alone was therefore enough to 
obtain acellular plasma, provided that the buffy coat layer was not disturbed during the 
pipetting step. 
Plasma samples from the previous study by Lo et al (Lo et al., 2000c) were 
heparinized samples. Heparin was claimed to be unsuitable for plasma DNA analysis 
because it was found to inhibit PCR process (Jen, Wu & Sidmnsky, 2000). One 
objective of present study was to compare plasma DNA concentrations from 
heparinized and EDTA samples, on both trauma and healthy subjects. Results showing 
that there was no difference between them. Hence, the findings from previous study 
using heparinized plasma were valid. Plasma harvested from both EDTA and 
heparinized blood samples can be use for plasma DNA quantitative analysis and the 
values are comparable. 
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To conclude, this study confirms that plasma DNA concentrations are elevated 
after trauma. The increased DNA concentrations correlated positively with injury 
severity, MODS and death. Using either EDTA or heparin as the anticoagulant would 
not affect the analysis. Besides, filtering plasma prior to DNA quantitation is not a 
necessary step for trauma samples. 
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CHAPTER 7 TEMPORAL CHANGES OF CELL-
FREE CIRCULATING DNA 
CONCENTRATION AFTER TRAUMA 
Introduction 
Serial studies of the changes of cell-free DNA in plasma and serum have been 
reported in cancer and pregnancy. The kinetics of EBV DNA concentrations after 
radiotherapy in patients with nasopharyngeal carcinoma and lymphoid malignancies 
was found to be an useful marker for prognosis and monitoring of cancer recurrence and 
progress (Lo et al., 1999b; Lo et al., 2000b; Lei et al., 2000). Studies on changes of 
fetal DNA concentrations in maternal plasma and serum during different stages of 
pregnancy allow the development of methods for detecting preterm labour (Leung et al., 
1998) and preeclampsia (Leung et al., 2001). Kinetic change of fetal DNA in normal 
and preeclamptic pregnant women after delivery also provides valuable information for 
the understanding of cell-free DNA clearance in circulation under normal and 
pathological conditions (Lo et al., 1999e; Lau et al., 2002). 
The concentration of DNA in plasma has been shown to increase in patients 
during the first few hours after trauma (Chapter 6), to correlate with injury severity and 
to predict late post-traumatic complications such as MODS, and death (Rainer et al., 
2001). However, the study involved only single blood samples taken from each patient 
and it was evident that there was considerable variation between patients. Such 
variability may be explained by rapid changes in the balance of liberation and clearance 
of DNA in the circulation, and thus may be due to differences in the timing of the 
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samples taken. I f such variation followed a standard pattern and temporal relationship, 
then defining any period of relative stability and reduced variance would improve our 
ability to diagnose and predict such complications. 
Little is known about the time course of changes in plasma DNA concentration 
in trauma patients, and much more accurate information about changes may be gained 
by taking serial rather than single blood samples. In this chapter, the concentration-time 
relationship of plasma DNA (using the P-globin gene as the detection marker) firstly in 
the initial few hours of injury and secondly after admission to the intensive care unit 
(ICU) were investigated. The different patterns of changes between patients with 
different injury severity and complications were also compared. 
Methods 
Subjects and study design 
Ethical approval was obtained from the Research Ethics Committee of The 
Chinese University of Hong Kong. Written or verbal consent was obtained from either 
the patient or a relative according to circumstances. 
Two separate parts were designed. Part 1 involved archived plasma samples 
collected between August 1996 and August 1999, for the preliminary investigation of 
early changes within the first three hours after injury. The samples were taken at 20 
minutes intervals as soon as the patients were admitted to the resuscitation room. The 
second part (Part 2) was conducted between July 2000 and October 2002, investigated 
daily changes in plasma DNA concentrations in severely injured patients admitted to the 
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ICU for the duration of their ICU stay and involved taking blood samples every day up 
to a maximum of 28 days. 
The criteria for patients to be recruited were the same as described in Chapter 6. 
A l l demographic, clinical history and examination results was collected as described in 
Chapter 6. Sex and age matched healthy subjects were recruited as controls. One 
EDTA blood sample was collected from each control subject. Verbal consents were 
obtained and each of them was asked to f i l l a questionnaire to make sure that they did 
not have diseases and not taking any medication 2 weeks prior to the study. 
End points 
The study end points were set at the time of discharge or death i f either were 
within 28 days of injury, or at 28 days post-injury i f the patient was still admitted. 
Patients discharged to a chronic care facility were considered discharged but those 
transferred to another hospital after sampling because of a shortage of beds were 
included in the study. 
Blood sampling and processing 
Part 1: Heparized plasma samples were retrieved from a —80°C freezer. 
A maximum of six samples had been collected from each patient. The plasma samples 
had been harvested from 4mL heparized blood after centrifugation at 1600g for 10 
minutes. 
Part 2: EDTA was used as the anticoagulant as it was thought to be a 
better anticoagulant. One blood sample was taken each day from each patient, 
withdrawn from the arterial line connected to the patient. Between 1 and 28 blood 
samples were withdrawn into EDTA tubes from each patient depending upon the 
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duration of their stay in the ICU. Blood samples collected were subjected to the 
centrifugation at 1600g x 10 minutes and then filtered through a 0.22|im filter. Plasma 
samples were transferred into clean plain polypropylene microtubes and were stored 
under -80 °C pending DNA quantitation. 
Two sets of control blood samples were also obtained from 54 healthy 
volunteers: 27 samples with heparin anticoagulant for Part 1 and 27 samples with 
EDTA as the anticoagulant for Part 2. 
Quantitation of DNA in plasma 
Procedures for the DNA extraction and RTQ-PCR followed that described in 
Chapter 5. 
Statistical analysis 
Descriptive statistics and non-parametric data comparison tests were carried out 
using Statview® for Windows version 5.0 Statistical Analysis Software (Abacus 
Concepts, SAS Institute, Gary NC, USA) as appropriate. As patients presented at 
variable time intervals from the onset of injury and the precise time of collection of 
samples was influenced by management procedures, the Mann-Whitney test was used to 
compare differences at each time point. Individual data are presented where appropriate 
(Matthews et al, 1990). 
Results 
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Part 1: Subjects studied in the first few hours after injury 
Twenty-five trauma subjects (mean age 38 years, range 18 - 70; 24 males) were 
recruited. This group included four patients with minor injury (ISS<9), ten patients 
with moderate injury (ISS 9 to 15)，seven patients with severe injury (ISS 16 to 25) and 
4 patients with very severe injury (ISS>25). Table 3 shows the number of trauma 
patient samples available at each time point for analysis. Figure 11 shows that plasma 
DNA concentrations were elevated within 20 minutes of injury and remained elevated 
for the subsequent 2 to 3 hours. Patients with ISS < 25 (n = 21) are grouped together in 
the figure and showed a persistently elevated DNA concentration for 3 hours. Patients 
with ISS > 25 (n = 4) are shown individually. A l l the DNA concentrations in patients 
with ISS > 25 were elevated above the mean of patients with ISS < 25. 
Within the first hour, the overall mean DNA concentration was 3-fold higher in 
patients with ISS > 25 (overall mean = 80 840 kilogenome-equivalents/L) than in 
patients with ISS < 25 (overall mean = 22 230 kilogenome-equivalents/L; p = 0.001, 
Mann-Whitney U test). The difference between them increased further in the second 
(overall mean = 125 000 versus 16 800 kilogenome-equivalents/L; p < 0.001) and third 
(overall mean = 128 700 versus 20 900 kilogenome-equivalents/L; p < 0.001) hours 
after injury. There was also a statistically significant difference between the means of 
the two groups at each time interval from 60 to 140 minutes (Mann-Whitney U test, p < 
0.05). 
Five patients (20%) later developed OF. Three of these had plasma DNA 
concentrations that were higher than the mean plasma DNA concentration of patients 
who did not develop OF during the first 3 hours after injury (Figure 12). Plasma DNA 
concentrations in most of the patients who did not develop OF returned to normal by 
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160 minutes after trauma. The difference between patients with OF and without OF are 
statistically significant from 80 to 160 minutes (p<0.05). 
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Table 3. Number of patient samples in Part 1 available for analysis at each time 
point. 
Minutes Total number Patients Patients Patients 
after of patients' with ISS < with ISS > without 
. . , 1， with OF ^ ^ injury samples 25 25 OF 
20 2 2 0 1 1 
40 8 5 3 2 6 
60 20 18 2 2 18 
80 22 18 4 3 19 
100 24 20 4 4 20 
120 25 21 4 5 20 
140 17 14 3 4 13 
160 6 4 2 3 3 
180 3 1 1 2 1 
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Figure 11. Early temporal relationships between mean plasma DNA 
concentration and severity of injury. 
Plasma DNA concentrations in control subjects ( • ) and trauma patients in the 
first three hours after trauma are shown. Patients with less severe injury (因；ISS < 25) 
were grouped together (mean 士 SE) while data from 4 patients with very severe injury 
(ISS > 25) were plotted individually (•，O, • , A ) . Where data points are missing, 
dotted lines connect available data readings. The x-axis represents the minutes after 
injury, where time “0” denote the controls. The plasma DNA concentrations are 
plotted on the y-axis. The vertical bars represent ±1 SEM. 
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Figure 12. Early temporal relationships between plasma DNA 
concentration and the development of OF. 
Early differences between plasma D N A concentrations in the first three hours 
after injury are shown with controls ( • ) . Patients who did not develop OF (因)were 
grouped together (mean 士 SE) while data from patients who developed OF were plotted 
individually (A, •， + , O , • ) . Where data points are missing, dotted lines connect 
available data readings. The x-axis represents the minutes after injury, where time "0" 
denote the controls. The plasma DNA concentrations are plotted on the y-axis. The 
vertical bars represent 1 SEM. 
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Part 2: Daily changes in subjects with severe injuries 
Thirty-six patients (mean age 44 years，25 males) admitted to the ICU were 
recruited in the study. Daily blood samples were withdrawn until their discharge from 
the ICU. The median ISS was 26 (interquartile range 17 to 34; range 9 to 41). Sixteen 
out of 36 patients (44%) developed MODS and 4 out of 36 patients (11%) died. Of the 
patients that died, 3 had MODS, and 1 did not develop MODS. Table 4 shows the 
number of patient samples available for analysis at each time point. 
Table 5 summarizes the mean plasma DNA concentrations in trauma patients 
with and without MODS for the first 5 days under the care of ICU. As shown in table 5 
and figure 13, the mean plasma DNA concentration on the day of injury (day 0) was 
elevated 300-fold in trauma patients compared with healthy controls (mean, 216 000 
versus 660 kilogenome-equivalents/L; Mann-Whitney U test, P<0.0001). The mean 
plasma DNA concentration in patients who did not eventually develop MODS was 
higher than those developed MODS on day 0, although the values were not statistically 
significant (Mann-Whitney U test, p = 0.822). On day 1 the mean plasma DNA 
concentration in all trauma patients fell 63% to 81 000 kilogenome-equivalents/L, but 
were still 120-fold higher than the controls. The mean plasma DNA concentration in 
patients with MODS was 88 000 kilogenome-equivalents/L (fell 45% from day 0) while 
patients without MODS fell 72% to 71 000 kilogenome-equivalents/L. The mean 
plasma DNA concentration in patients without MODS dropped even markedly on day 2 
(99% from day 0) and continue to decrease slowly for the subsequent few days until 
they were discharged from ICU. The mean plasma DNA concentration in patients with 
MODS always higher than in patients without MODS from day 1 to day 5. The 
difference between patients with MODS and without MODS was significant on days 2, 
3，4 and 5 (Mann-Whitney U test, p < 0.05). The daily mean plasma DNA 
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concentration in patients with MODS decreased very slowly until they were discharged 
from ICU to levels still higher than that of patients without MODS and controls. 
There were total 16 patients developed MODS and four of them died early. 
Figure 14(a) and (b) show the daily changes in plasma concentration in the 12 patients 
who remained in ICU for seven days or more, who developed MODS and who 
eventually survived until discharge from ICU (there were total 16 patients developed 
MODS and 4 of them died early). Although there was considerable individual variation 
in the peak plasma DNA concentration measured on day 0, in all patients the level fell 
dramatically by day 1. In most patients this was followed by a rise in plasma DNA 
concentration which lasted several days, coincided with MODS, and which then began 
to fall further towards normal values. In some subjects, this trend was not immediately 
obvious because the initial value was extremely high (no. 4, 6 and 11) and values on 
subsequent days were relatively low. Plasma DNA concentrations fell about 90% from 
the initial day of injury but in no case did it reach normal levels prior to discharging the 
patients from ICU. 
Four of the 36 patients died. Three of these patients developed MODS and died 
within three days of injury and of admission to ICU. In two of these patients with 
MODS, there was a rising trend in circulating plasma DNA concentrations whilst in the 
third there was a falling trend (data not shown). The fourth patient died within a day of 
injury. 
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Table 4. Number of patient samples in Part 2 available for analysis at each time 
point. 
Days after Total number of Samples from Samples from 
injury samples^ patients with patients without 
MODS MODS 
0 25 10 15 
1 28 16 12 
2 19 14 5 
3 17 13 4 
4 12 9 3 
5 11 10 1 
6 12 12 0 
7 10 10 0 
8 10 10 0 
9 10 10 0 
10 8 8 0 
11 7 7 0 
12 4 4 0 
13 7 7 0 
14 5 5 0 
15 5 5 0 
16 5 5 0 
17 4 4 0 
18 2 2 0 
19 2 2 0 
20 2 2 0 
21 2 2 0 
22 2 2 0 
23 2 2 0 
24 2 2 0 
25 2 2 0 
26 2 2 0 
27 2 2 0 
28 2 2 0 
^Total number of samples do not match with the total number of patients either because some 
patients died, some patients were discharged from ICU, or because on some days some patients 
were not available for blood collection. In eleven patients, samples were not available on day 0, 
but were available on subsequent days. 
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Table 5. The mean plasma DNA concentratins in the controls, all trauma patients 
and the 2 trauma subgroups: those with MODS and those without MODS, during 
the first 5 days in ICU. 
^ D a y s Mean (± SD) Mean (± SD) Mean (± SD) P-value 
plasma DNA plasma DNA plasma DNA (between 
after concentration concentration concentration patients 
(kilogenome- (kilogenome- (kilogenome- with and 
injury equivalents/L) in equivalents/L) in equivalents/L) in without 
all trauma patients trauma patients trauma patients MODS, 
with MODS without MODS Mann-
Whitney 
test) 
0 220 000 (390 000) 160 000 (240 000) 250 000 (460 000) 0.82 
1 81 000 (201 000) 88 000 (210 000) 71 000 (200 000) 0.21 
2 19 000 (34 000) 25 000 (38 000) 3 200 (3 800) 0.01 
3 21 000 (49 000) 27 000 (55 000) 3 400 (3 000) 0.04 
4 14 000(16 000) 18 000(17 000) 2 800 (1 700) 0.01 
5 9 700 (7 000) 10 000 (7 800) 2 300* 0.21 
Controls 600 600 600 --
* no SD value because only one patient without MODS enrolled on day 5. 
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Figure 13. Daily temporal relationships between plasma DNA 
concentration and MODS. 
Mean plasma DNA concentrations in trauma patients between the day of injury 
and subsequent days to day 28. Patients were divided into those with MODS (+) and 
those without MODS (〇).The horizontal dotted line represent the mean plasma DNA 
concentration of controls. The x-axis represents the days after injury and the plasma 
DNA concentrations are plotted on the y-axis with a logarithmic scale. The vertical bars 
represent ±1 SEM. The difference between patients with and without MODS are 
statistically significant on days 2 to 4 (p<0.05, Mann-Whitney U Test). 
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Figure 14a & 14b. Sequential follow-up of plasma DNA concentration in trauma 
patients who developed MODS and survived. 
Daily changes of plasma DNA concentrations in individual patients who 
developed MODS and survived (A). The horizontal dotted line represent the level of 
mean plasma DNA concentration of controls. The x-axis represents the days after injury 
whilst DNA concentrations are plotted on the 少-axis. Individual ISS values are included 
in each plot. 
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Discussion 
This study shows serial hourly and daily changes in plasma DNA concentrations 
in patients after trauma, assessed by measuring P-globin sequence concentrations using 
RTQ-PCR. In Chapter 6 and in previous study (Lo et al., 2000c), plasma DNA was 
elevated significantly within minutes of injury, and that elevated concentrations 
correlated positively with injury severity and OF. Plasma DNA has been suggested as a 
potential marker for the prediction of post-traumatic OF, and a prediction model for 
post-traumatic OF was developed by using plasma DNA levels and other clinical 
variables (Rainer et al., 2001). However, these studies provided little information on 
temporal changes in DNA in plasma after trauma and no information for individual 
variation or trends. In this study the temporal variations of this plasma DNA 
concentration, and its relationship with OF and MODS were carefully investigated. 
Patients irrespective of injury severity were recruited in the first part while only 
moderately to severely injured patients need to be treated in ICU were recruited in the 
second part study. Only ICU patients were recruited in daily-serial study under the care 
of ICU. Higher plasma DNA concentrations were found in more severely injured 
patients (Chapter 6), hence more dramatic changes were expected to be observed from 
ICU patients. 
The results would suggest that the elevation of plasma DNA in patients suffering 
from trauma is virtually universal. The elevation started as early as 20 minutes after the 
event. Within two hours, plasma DNA fell towards normal in less severely injured 
patients but remained elevated in the first few hours after injury in patients who later 
developed OF. In all severely injured patients initially admitted to ICU, plasma DNA 
concentrations were grossly elevated and these increases were possibly associated with 
secondary injury associated with early surgical procedures to treat trauma. Patients with 
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MODS remained in the ICU for a longer period than patients without MODS but in the 
first few days after admission there was a significant difference in mean plasma DNA 
levels between the two groups. This study showed that there was considerable variation 
in the degree of early plasma DNA elevation observed in patients admitted to ICU and 
who developed MODS, but in general the trend of an extremely sharp early peak, 
followed by a later damp, more prolonged elevation was observed in nearly all subjects. 
Increased plasma DNA post-trauma may due to tissue injury - the more severe 
the injury, the more DNA is likely to be released into the circulation. Impaired 
clearance is another possible reason for devalued plasma DNA. Impaired clearance of 
plasma fetal DNA has also been observed in pregnant women who had preeclampsia 
(Lau et al 2002). 
Herriott et al (Herriott, Connolly & Gupta, 1961) has demonstrated the existence 
of nucleases in plasma which indicated a role for the degradation of purified DNA 
injected into the animals in their experiment. This evidence was further elevated by Lo 
et al (Lo et al., 1999f) that the nucleases only play a partial role in the removal of 
circulating fetal DNA in pregnant women, suggested the contribution of other organ 
systems. Organ systems such as liver (Emlen & Mannik, 1978) and kidney (Tsumita & 
Iwanaga, 1963) are believed to be responsible for circulating DNA clearance. However 
these studies involved in vivo animal models and injection of purified DNA molecules, 
which could not be fully extrapolated to cell-free DNA liberated within a human body. 
With regard to trauma and preeclampsia, organ systems may be influenced by the 
impaired balance of hormones under the unfavorable condition for example, to render 
the efficiency of cell-free DNA clearance. 
In conclusion, plasma DNA concentrations are elevated early after injury, are 
higher in patients with severe injuries and in those who develop OF. These levels 
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remain elevated for days after injury especially in patients with MODS. These findings 
may be used for risk-stratification and monitoring post-traumatic disease progress. 
Besides, evaluation of the plasma DNA variation pattern after injury further enhances 
the accuracy of the analysis of post-trauma plasma DNA concentration. 
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SECTION 4 
CELL-FREE CIRCULATING DNA CONCENTRATION AFTER 
STROKE 
The chapters in this section investigate the early changes of cell-free circulating 
DNA concentration in the plasma of patients suffered from acute stroke, with an added 
attempt to compare it's predictive value to the mortality and disability at discharge and 
6-month after stroke onset. Temporal change of the circulating DNA is also 
investigated. 
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CHAPTER 8 RELATIONSHIP OF CELL-FREE 
CIRCULATING DNA 
CONCENTRATION IN PATIENTS 
WITH STROKE 
Introduction 
At present, stroke diagnosis is mainly based on modem neuroradiological 
imaging techniques such as computerized tomography (CT), magnetic resonance 
imaging (MRI) and ultrasound (Chapter 3). Clinical neurological examination is helpful 
when neurological function is largely intact but is of lesser value in assessing infarct 
volume or in patients who are comatose after cerebral infarction. 
Unlike the acute coronary syndrome, which has a number of non-specific and 
specific plasma or serum markers which may be used to both diagnose and to assess the 
severity of myocardial infarction, no similar established markers exist for patients with 
stroke. The blood brain barrier is compromised in many patients with stroke and the 
liberation of neurobiochemical protein markers into the circulation may allow the 
pathophysiology, progress and prognosis of patients with cerebrovascular disease to be 
further evaluated (Abraha et al., 1997; Buttner et al, 1997; Stevens et al., 1999; 
Wunderlich et al., 1999). Although raised levels of several neurobiochemical protein 
markers (e.g. S-100 and NSE) have been detected in the peripheral blood of patients 
with stroke so far none have found a place in clinical practice. 
Circulating DNA in plasma concentration is altered quantitatively in a variety of 
pathologic conditions, including preeclampsia (Lo et al., 1999e; Leung et al., 2001), 
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cancer (Leon et aL, 1977), graft rejection (Lo et al., 1998b) and trauma (Lo et al., 
2000c). Although the mechanisms by which nucleic acids are released into the 
circulation are unknown, it is likely that cell death is one major factor (Foumie et aL, 
1993; Foumie et al, 1995). As both haemorrhagic and ischaemic stroke involve cell 
death and disruption of the blood brain barrier, one hypothesis is that DNA would be 
liberated into the plasma early after the onset of stroke and might be useful for assessing 
disease severity and for predicting mortality. Elevated plasma DNA concentration have 
been demonstrated in trauma patients in the previous chapters, based on a similar 
hypothesis. 
Hence, the purposes of this study was to investigate the early changes of plasma 
DNA concentrations in patients presenting with stroke, and the correlation between 
DNA and stroke severity, types and outcome of stroke. 
Materials and Methods 
Subjects 
Approval was obtained from the Research Ethics Committee of The Chinese 
University of Hong Kong to conduct a prospective study investigating the role of 
plasma DNA in the diagnosis and prognosis of patients presenting with stroke-like 
syndromes at the Prince of Wales Hospital. 
Eligible patients aged >18 years presenting to the emergency department with a 
stroke-like syndrome were recruited consecutively into the study. Exclusion criteria 
included multiple trauma, craniocerebral or cervical trauma, meningitis, encephalitis or 
other sepsis, hypertensive encephalopathy, intracranial tumor, seizures with persistent 
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neurological signs (Todd's paralysis), Bell's palsy, migraine, metabolic disturbances 
(for example hypoglycaemia, hyperglycaemia), post-cardiac arrest, drug overdose, 
endocrine disorders (for example myxoedema), renal failure, psychiatric syndromes, or 
shock with hypoperfusion. Patients were also excluded if the time from symptom onset 
to blood sampling was greater than 24 hours. Informed, written consent was obtained 
either from the patient or a relative in all cases. Twenty healthy age and sex-matched 
subjects were recruited as controls. 
Definitions and data collection 
Stroke was defined as the acute occurrence of focal neurological signs lasting for 
more than 24 hours in a different neuroanatomical location from that of any previous 
stroke, or worsening of an existing deficit that lasted for more than one week, or more 
than 24 hours if accompanied by a new lesion on neuroimaging (NINDS, 1990). 
Stroke-like syndrome was defined according to the following criteria: firstly, if the 
patient had a facial droop, arm drift or weakness, or abnormal speech (compatible with 
the Cincinnati Prehospital Stroke Scale) (Kothari et al., 1999); secondly, if the patient 
had an altered level of consciousness with no other primary cause for neural change 
such as obvious associated seizures, hyperglycemia or hypoglycemia (compatible with 
the Los Angeles Prehospital Stroke Scale) (Kidwell et al., 1998; Kidwell et al., 2000). 
Demographic and previous medical data were collected including age, sex, 
symptom onset time, history of previous strokes, seizures, hypertension, diabetes 
mellitus, ischaemic heart disease, atrial fibrillation, hyperlipidaemia, smoking, 
antithrombotic and other medication. An assessment of each patient's previous health 
was made using the Pre-Stroke Modified Rankin Scale, a simplified overall assessment 
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of function in which a score of 0 indicates the absence of symptoms and a score of 5 
indicates severe disability (van Sweiten et aL, 1988). 
In order to determine the exact nature and cause of the stroke-like syndrome, 
patients received a standard clinical, laboratory and imaging workup, including cerebral 
computed axial tomography (CT) and magnetic resonance imaging (MRI). CT (N=88) 
and MRI (N=71) scans were not possible for all cases as some patients were too ill for 
two scans and some patients had contraindications for MRI. Details of CT and MRI 
procedures are available in Appendix 3. 
Patients were classified as having a transient ischaemic attack (TIA) if their 
symptoms and signs resolved within 24 hours. Stroke cases were classified to one of 
two groups: intracerebral haemorrhage or cerebral infarction. 
The severity of stroke was assessed clinically using two methods. The National 
Institutes of Health Stroke Scale (NIHSS) is a 42-point scale that quantifies neurological 
deficit in 11 categories such that normal function with no deficit receives a score of zero 
(Spiker & Kongable, 2000). The Glasgow Coma Score (GCS) is a 15-point score which 
ranges from 3 to 15 and assesses visual, motor and verbal responses to stimulus such 
that a score of 15 gives a normal response and 3 is associated with severe dysfunction 
(Teasdale & Jennet, 1974) (Appendix 4). 
Outcome 
The primary outcome measures were mortality in hospital or within 28 days 
whichever was sooner, and mortality and Post-Stroke Modified Rankin Score (PR) at 
six months after the onset of symptoms. Accordingly, the outcome of patients were 
classified as spontaneous neurological improvement or good outcome (PR grades 0-2), 
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and poor outcome or not improved or death (PR grades 3-5) (Arboix et al., 2003) 
(Appendix 5). 
Blood Sampling and Processing 
A 3-mL blood sample was withdrawn from the antecubital vein of each patient, 
as soon as the patients were admitted and were collected into tubes containing EDTA. 
A 3-mL EDTA blood sample was also withdrawn from each of the twenty age-
and sex-matched healthy controls. 
All blood samples were centrifuged at 1 600xg for 10 minutes, and plasma was 
then transferred into plain polypropylene tubes, and stored at -80^C pending further 
analysis. 
Quantitation of DNA in Plasma 
Procedures for the DNA extraction and RTQ-PCR followed that described in 
Chapter 5. 
Statistical Analysis 
Descriptive statistics and data comparison tests - Mann-Whitney and Kruskal-
Wallis tests - were carried out using Statview® for Windows version 5.0 Statistical 
Analysis Software (Abacus Concepts, SAS Institute, Gary NC, USA) as appropriate. 
Correlations were determined using Spearman Rank or Kruskall-Wallis tests whilst 
Receiver Operating Characteristic (ROC) curve analysis was carried out using the 
MedCalc 5.0 software. 
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Results 
Characteristics of 88 adult patients who were enrolled in the study with a stroke-
like syndrome are shown in Table 6. Although the majority of patients were elderly and 
had a number of risk factors for stroke, 71 (81%) had no significant health disability 
prior to their acute admission as assessed using the Pre-Stroke Modified Rankin Score. 
Six patients died within 28 days of hospital admission and 11 within six months. In 11 
cases, there were no signs of haemorrhage or infarction on neuroimaging but persistent 
clinical features of stroke which were unexplained by any other cause. These cases 
were classified as having had a cerebral infarction. The majority of patients presented 
within the first few hours of symptom onset. Twenty-four subjects (mean age 70 years; 
11 male) in the healthy control group did not differ significantly from the patient group 
in either age (p = 0.23, Mann-Whitney U Test) or sex (p = 0.64, Mann-Whitney U Test). 
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Table 6. Characteristics of the 88 Patients Presenting to Hospital with Stroke"^ 
Characteristics Value 
Age (yr) 74 [16] 5 0 - 9 2 ^ 
Male sex - no. of patients (%) 45 (51) 
Stroke risk factors - no. of patients (%) 
Hypertension 53 (60) 
Diabetes mellitus 21 (24) 
Ischaemic Heart Disease 11 (13) 
Atrial Fibrillation 15(17) 
Hyperlipidaemia 9 (10) 
Active smoking 18 (21) 
Ex-smoking 22 (25) 
Previous stroke 24 (27) 
Pre-Stroke Modified Rankin core - no. of patients (%) 
Asymptomatic 71 (81) 
No significant disability 14(16) 
Slight disability 2 (2) 
Moderate disability 0 
Moderately severe disability 1(1) 
Severe disability 0 
Time from onset of symptoms to blood sample (hrs) 8 [12] 1-24 
Pulse rate (per minute) 77 [22] 24-172 
Blood pressure (mm Hg) 
Systolic 169 [55] 100-272 
Diastolic 88 [26] 40-142 
Blood glucose (mmol/L) 6.8 [3.5] 4.2-20 
Glasgow Coma Score - no. of patients (%) 
3 - 8 4(5) 
9 - 1 2 9(10) 
13 - 15 75 (85) 
NIHSS score - no. of patients (%)J 
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0 - 1 7 (8) 
2 - 8 40 (46) 
9 - 4 0 41 (47) 
Stroke Types — no. of patients (%) 
Infarct 70 (80) 
Haemorrhage 11 (13) 
Transient Ischaemic Attack - no. of patients (%) 7 (8) 
* All continuous data are expressed as medians [interquartile range] range. Numbers 
may not sum to 100 because of rounding, multiple factors (for example risk factors) or 
absent data. 
t NIHSS, National Institutes of Health Stroke Scale. 
117 
^^^^^^^^^^^^ Cg/^gg Circulating DNA Concentration in Patients with Stroke 
Plasma DNA concentration and the severity of stroke 
Stroke severity was assessed clinically by GCS and NIHSS. As shown in figure 
15, plasma DNA concentration was higher in patients with lower GCS values i.e. more 
severe dysfunction. The median plasma DNA concentration in patients with GCS = 03-
08 (4 600 kilogenome-equivalents/L; n=4) was 4.5-fold higher than the controls (1 000 
kilogenome-equivalents/L) and GCS = 13-15 (i.e. patients of least dysfunction) (1 000 
kilogenome-equivalents/L, n=75); and 3-fold higher than the patients with GCS = 09-12 
(1 600 kilogenome-equivalents/L; n=9). Plasma DNA concentration was significantly 
correlated with the GCS values (p = 0.006, Kruskal-Wallis Test). 
On the other hand, median plasma DNA concentrations among different 
subgroups as measured by NIHSS were similar (figure 15). There was no correlations 
between the plasma DNA concentration and NIHSS (p = 0.3，Kruskal-Wallis Test). 
In those patients who presented with an NIHSS > 8 (i.e. more severe, n=41), 
median plasma DNA concentrations were higher in those who died (n=6) compared 
with those patients who survived to 28 days (2 100 versus 1 000 kilogenome-
equivalents/L; p= 0.002, Mann-Whitney U Test) and the seven died within 6 months (72 
250 versus 970 kilogenome-equivalents/L; p=0.003, Mann-Whitney U Test) (figure 16). 
Plasma DNA concentration in different types of stroke 
Seventy patients were classified as having infarct stroke and 11 patients were 
classified as having haemorrhagic stroke. Seven patients were diagnosed TIA. 
Figure 17 shows the plasma DNA concentrations in patients of different types of 
stroke. No differences can be observed in the median plasma DNA concentrations 
among various groups (p = 0.69, Kruskal-Wallis Test). 
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Plasma DNA concentration and the outcomes after stroke 
Outcome after stroke was measured as mortality at 28-day, mortality at 6-month 
and Post-Stroke Modified Rankin Score (PR) at 6-month, after the onset of stroke 
symptoms. 
Figure 18 shows the mortality at 28 days and 6 months. The median plasma 
DNA concentration of patients who died within 28 days (2 125 kilogenome-
equivalents/L; n=6) and 6 months (2 000 kilogenome-equivalents/L; n= l l ) were about 
doubled those survived (1 000 kilogenome-equivalents/L, both at 28-day and 6-month) 
and controls (1 000 kilogenome-equivalents/L). The differences of median plasma 
DNA concentration between patients who died at 28-day and 6-month were statistically 
significant from those survived (p = 0.002 and p = 0.0003 respectively, Mann-Whitney 
U Test). 
In figure 19，the disability of patients after stroke were assessed by PR at 6-
month. PR = 0-2 represents patients with minimal disabilities (n=48), while PR = 3-6 
represents patients with more severe disability (n=40, including death). The median 
plasma DNA concentrations in PR = 0-2 and PR = 3-6 were 1000 and 1250 
kilogenome-equivalents/L respectively which was statistically significant (p — 0.02, 
Mann-Whitney U Test). Although the difference between them was small. 
The ROC curve analysis for comparing the sensitivity and specificity of plasma 
DNA concentrations for mortality at 28-day, mortality at 6-month and the disability 
(PR>2) at 6-month are shown in figure 20. The areas under the curves, sensitivity and 
specificity are summarized in table 7. 
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Figure 15. Plasma DNA concentrations and severity of stroke. 
Plasma DNA concentration (y-axis) in patients with different severity of stroke, 
as measured by GCS and NIHSS {x-axis). (a) GCS = 03-08 indicates the most severe 
group whereas GCS = 13-15 is the least severe group. Plasma DNA concentrations 
were significantly correlated with GCS values (p二0.006, Kruskal-Wallis Test), (b) 
NIHSS = 0-1 is the least severe group and NIHSS = 8 is the most severe group. No 
statistical significant differences were found between plasma DNA concentration and 
NIHSS values. The lines inside the boxes denote medians whilst the boxes mark the 
interval between the 25th and 75th percentiles. The whiskers denote the interval 
between the 10th and 90th percentile and outliers are illustrated as black dots. 
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Figure 16. Plasma DNA concentration and mortality in stroke patients 
with NIHSS > 8 
Box plots of plasma DNA concentrations (y-axis) in the mortality (x-axis) of 
patients within (a) 28 days and (b) 6 months are shown. There are statistically 
significant differences between patients who died and survived at 28 days (p=0.002, 
Mann-Whitney test) and at 6 months (p=0.003, Mann-Whitney Test). The lines inside 
the boxes denote medians whilst the boxes mark the interval between the and 
tVi tVi 
percentiles. The whiskers denote the interval between the 10 and 90 percentile and 
outliers are illustrated as black dots. 
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Figure 17. Plasma DNA concentrations and different types of stroke. 
Plasma DNA concentrations (y-axis) in patients with haemorrhagic stroke, 
infarct stroke, or having TIA {x-axis). The lines inside the boxes denote medians whilst 
the boxes mark the interval between the and 75th percentiles. The whiskers denote 
the interval between the and percentile and outliers are illustrated as black dots. 
There was no statistically difference of plasma DNA concentrations among the different 
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Figure 18. Plasma DNA concentrations and mortality in patients 
presenting with stroke. 
Plasma DNA concentrations {y-axis) in patients who survived or died (a) within 
28 days and (b) within 6 months of presentation {x-axis). The lines inside the boxes 
th th • 
denote medians whilst the boxes mark the interval between the 25 and 75 percentiles. 
The whiskers denote the interval between the and percentiles and outliers are 
illustrated as black dots. The difference between the groups was statistically significant 
(p = 0.002 for 28-day and p = 0.0003 for 6-month, Mann-Whitney U Test). 
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Figure 19. Plasma DNA concentrations and disability in patients 
presenting with stroke 
Plasma DNA concentrations (y-axis) in patients who disability assessed by PR = 
0-2 and PR = 3-6 at 6 months of presentation {x-axis). The lines inside the boxes denote 
medians whilst the boxes mark the interval between the 25 and 75 percentiles. The 
whiskers denote the interval between the 10丈卜 and 90让 percentile and outliers are 
illustrated as black dots. The difference between the two patient subgroups was 
statistically significant (p = 0.02，Mann-Whitney U Test). 
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Figure 20. ROC curve analysis of plasma DNA concentration in stroke 
patients� 
ROC curve analysis of plasma DNA concentrations for the prediction of (a) 
mortality at 28-day, (b) mortality at 6-month and (c) PR>2 at 6-month, after the onset of 
stroke symptoms. Values indicated on the x- and y-axes are expressed in percentages. 
Area under the ROC curves: (a) 0.888, (b) 0.836 and (c) 0.753. 
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Table 7. The areas under the ROC curves, the sensitivities and specificities of 
plasma DNA concentrations (kilogenome-equivalents/L) for the predictions of 
mortality at 28-day, mortality at 6-month and PR>2 at 6-month. 
Area under ROC � ... •‘ ^ •‘ 
Sensitivity Specificity 
c u r v e 
(SE; 95% CI) (950/0 CI) (95% CI) 
Mortality at 0.888 100 74.1 
28-day (0.089; 0.803 - 0.945) (54.1 - 100.0) (63.6 - 83.4) 
Cut off: plasma DNA concentration > 1 400 
kilogenome-equivalents/L 
Mortality at 6- 0.836 90.9 68.8 
month (0.077; 0.742-0.906) (58.7-98.5) (57.3 -78 .9) 
Cut off: plasma DNA concentration > 1 150 
kilogenome-equivalents/L 
PR>2 at 6- 0.753 53.3 87.9 
month (0.058; 0.649-0.839) (34.3-71.6) (76.7-95.0) 
Cut off: plasma DNA concentration > 1 500 
kilogenome-equivalents/L 
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Plasma DNA concentration in patients with negative neuroimaging 
Seventeen patients (20%) had clinical stroke but had normal CT and MRI scans. 
Differences could be observed from the plasma DNA concentration by comparing the 
different outcomes. 
Within this subgroup, patients who died within 6 months (n=2) had a 5-fold 
higher plasma DNA concentration than those survived (figure 21) (p = 0.04, Mann-
Whitney Test). Moreover, patients with more severe disabilities (PR = 3-6; n=6) had a 
1.6-folder higher (1 294 kilogenome-equivalents/L) and statistically significant plasma 
DNA concentration than the patients of PR = 0-2 (800 kilogenome-equivalents/L； 
n - l l ; p = 0.04, Mann-Whitney U Test). 
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Figure 21. Plasma DNA concentrations and outcomes in patients with 
negative neuroimaging. 
Plasma DNA concentrations (y-axis) in patients who had normal neuroimaging 
results and who (a) survived or died and (b) assessed with Post-Stroke Modified Rankin 
Score (PR) = 0-2 or PR = 3-6, within six months of presentation (x-axis). The lines 
inside the boxes denote medians whilst the boxes mark the interval between the 25 and 
75th percentiles. The whiskers denote the interval between the and percentile 
outliers are illustrated as black dots. The differences of plasma DNA concentration of 
(a) between patients who died and survived, (b) between patients with PR = 0-2 and PR 
=3-6, were statistically significant (p 二 0.04 in both situations, Mann-Whitney U Test). 
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Discussion 
This study shows that circulating plasma DNA concentration, by measuring fi-
globin sequence using RTQ-PCR, increases in patients in the first 24 hours of acute 
stroke. Plasma DNA concentrations correlate with stroke severity. We have further 
shown that plasma DNA measurement may be useful for early risk-stratification and for 
predicting in-hospital and six-month disability and mortality. Plasma DNA 
concentrations may also be useful for risk-stratification and for predicting the six-month 
mortality and Post-Stroke Modified Post-Rankin outcome scores in patients with 
clinical stroke but negative neuroimaging. 
Previous studies have reported elevated serum neurobiochemical markers - S-
100 protein and neuron-specific enolase (NSE) — in the peripheral circulation of patients 
after stroke but failed to demonstrate that these markers offered any additional 
advantage over current clinical assessment scales, risk factors or neuroradiological 
techniques (Abraha et al., 1997; Buttner et al., 1997; Stevens et al., 1999; Wunderlich et 
al., 1999). Correlations have been observed between the protein marker levels, infarct 
size and NIHSS scores, and elevated levels predict disability and mortality. However, 
in our study we have demonstrated not only that plasma DNA concentrations are 
elevated in patients with stroke and correlate with stroke severity, but also that these 
concentrations considerably improve our ability to objectively predict mortality and six-
month Post-Stroke Modified Rankin Score over and above what is offered by current 
neuroimaging techniques and subjective clinical scoring methods. 
Plasma DNA concentration does not appear to help differentiate between 
hemorrhagic stroke and cerebral infarction. Thus any role in guiding therapeutic 
intervention is presently unclear. Multiple factors, time relationships and small cerebral 
abnormalities at critical sites may dramatically affect the clinical presentation and 
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outcome but in general it appears that patients with more dramatic clinical presentations 
and outcomes had a general trend towards raised plasma DNA concentrations. 
There is a good correlation between the plasma DNA concentration and the GCS 
but no correlation with the NIHSS. Both scales have been used for the assessment of 
stroke severity in clinical trials but they have different baseline measurements. GCS 
focuses on loss of consciousness i.e. to quantify the depth and duration of coma 
(Teasdale & Jennet，1974); whereas NIHSS is a comprehensive neurological assessment 
scoring system (Spiker & Kongable, 2000), to reflect the overall degree of neurological 
deficit (Muir et al, 1996). 
Similar to mechanical injury, cell-free DNA increases after stroke require further 
study but are likely to be a result of increased liberation from damaged cells. Stroke 
involves a complicated cascade of events involving cerebral ischaemia, altered cerebral 
blood flow, inflammation, the production of reactive oxygen radicals, neuronal necrosis 
and apoptosis，and neurological dysfunction (Yang et al., 2001; Sairanen et al., 2001; 
Graham & Chen, 2001; Reed, 2000; MacManus & Buchan, 2000). DNA may be 
liberated from cells undergoing apoptosis or necrosis and elevated levels have been 
noted in other conditions involving organ, tissue and cellular injury such as cancer 
(Stroun et al, 1987; Foumie et al., 1995). Which of these mechanisms are involved in 
patients with stroke is not known but cellular ischemia and tissue infarction undoubtedly 
occur and are associated with disruption of the blood brain barrier such that increased 
local liberation of DNA from cells might result in increased systemic plasma levels. As 
P-glohin is found in all nuclear cells in the body, we cannot rule out the possibility that 
other non-cerebral tissue pathology associated with cell death or DNA release may 
contribute to raised levels of plasma DNA. 
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The differences of plasma DNA concentrations between stroke patients and 
healthy controls is smaller than that between trauma patients and the respective control 
group. The controls enrolled in present study were older (mean age = 69，range 64 -
74). Whether or not plasma DNA concentration is affected by age，and/or sex, 
remained to be elucidated. Unlike trauma, the tissue injury due to stroke may be only 
confined to the brain tissue, is relatively small when compared with the whole body, and 
therefore, the cell-free DNA amount released into the circulation is expected to be less 
than after trauma. 
Some patients had a stress response with associated hyperglycaemia. If stroke 
rather than hyperglycaemia, was found to be the primary cause of the neurological 
dysfunction, then the patient was still included in the study. 
A cut-off value of <1400 kilogenome-equivalents/L yields a sensitivity of 100%, 
a specificity of 74.1 % for determining mortality at 28-day. Further studies are required 
to validate and refine the optimal plasma DNA cut-off levels for diagnosis and 
prognosis. 
In conclusion, this study reports a DNA-based marker for stroke and the findings 
suggest that measuring plasma DNA may be a potentially useful, relatively quick and 
non-invasive test for monitoring patients presenting with stroke-like symptoms. A 
simple blood test might be used to predict mortality and morbidity and to stratify 
patients entering into clinical trials. Where CT/MRJ is either unavailable or yields no 
obvious acute abnormality, a plasma DNA test may also help to predict likely mortality 
or functional outcome. 
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CHAPTER 9 DAILY CHANGES 
OF CELL-FREE CIRCULATING DNA 
CONCENTRATION AFTER STROKE 
Introduction 
It should be of great interest to investigate the serial change of plasma DNA 
concentration in patients presenting with stroke. Serial changes of plasma DNA 
concentration are significant in the monitoring of disease and treatment responses in 
cancer patients post-treatment (Lo et al., 1999b), preeclamptic women after delivery 
(Lau et al.’ 2002) and in trauma patients with MODS (Chapter 7). Decreasing plasma 
DNA concentrations are apparent in patients recovery from illness whereas the levels 
increase or are maintained at higher levels in patients who are more seriously suffered. 
Therefore the purpose of this chapter is to investigate the serial changes of 
plasma DNA concentration in stroke patients, on a daily basis, from the day of stroke 
onset. 
Materials and Methods 
Subjects，Definitions and Data collection，Outcome 
Same as Chapter 8. 
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Blood Sampling and Processing 
A maximum of five 3-niL blood samples were withdrawn from the antecubital 
vein of each patient during the first five days from the day of onset. One 3-mL blood 
sample was taken from each patient each day. 
The plasma DNA concentration results from the twenty healthy controls from 
Chapter 8 were also used as well in this chapter. 
Blood processing followed that mentioned in Chapter 8. 
Quantitation of DNA in Plasma 
Procedures for the DNA extraction and RTQ-PCR followed that described in 
Chapter 5. 
Statistical Analysis 
Descriptive statistics and data comparison tests — Mann-Whitney and Kruskal-
Wallis tests — were carried out using Statview® for Windows version 5.0 Statistical 
Analysis Software (Abacus Concepts, SAS Institute, Gary NC, USA) as appropriate. 
Results 
A total of 5 stroke patients were recruited in this study (3 male; mean age 76 
years, range 65 - 89). None of the patients died within 6 months. 
Figure 22 shows the daily changes of plasma DNA in the 5 patients presented as 
a group. The graph shows a decreasing trend of the plasma DNA concentration in the 
first 5 days after stroke onset, but two distinct peaks can be observed on day 0 (mean = 
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3 300 kilogenome-equivalents/L) and on day 2 (mean = 2 600 kilogenome-
equivalents/L). Despite a marked elevation of plasma DNA observed on day 0, there 
was no significant difference when compared with the controls (p = 0.2, Mann-Whitney 
test). In fact, only 2 out of 5 patients had the plasma DNA elevated on day 0 (figure 
23). However, the plasma DNA concentration on day 2 was significantly higher than 
the controls (p = 0.005, Mann-Whitney U test), with 4 patients showing an increase in 
the plasma DNA concentration on day 2 (figure 23). Furthermore, it is clearly shown in 
figure 23 that the plasma DNA concentrations fell after day 2 to normal levels, except in 
one patient (number si 85) which elevated again on day 4. 
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Figure 22. Daily changes of plasma DNA concentration after stroke. 
The plasma DNA concentration (mean 土 SEM) in 5 patients measured on days 0 
to 4 after acute stroke (•) and twenty controls (O). The x-axis represents the days after 
injury and the plasma DNA concentrations are plotted on the y-axis. DO — D4 denoted 
samples taken from day 0 - day 4. The vertical bars represent 士 1 SEM. The 
differences among the 5 days of study are statistically significant (p —  0.04, Kruskal-
Wallis Test) with and without the controls. 
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Ischaemic stroke Haemorrhagic stroke Negative neuroimaging 
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Figure 23. Daily changes of plasma DNA concentration in individual 
stroke patients. 
The release patterns of plasma DNA concentration in 5 individual stroke patients 
during the first 5 days after the onset of stroke. The horizontal dotted line represent the 
level of mean plasma DNA concentration of controls. Where data points are missing 
(patient si97), broken lines connect available data. The x-axis represents the days after 
injury and the plasma DNA concentrations are plotted on the y-axis. DO — D4 denoted 
samples taken from day 0 - day 4. Blood samples from si95 and si96 only available 
from day 0 to day 3; while day 3 sample was missing for si97. 
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Discussion 
This study shows the serial daily changes of plasma DNA concentrations in 
patients presenting with stroke. Unlike in trauma cases where plasma DNA 
concentrations in most patients showed the highest level on the day of injury, only some 
of the stroke patients gave significant elevation of plasma DNA concentrations on the 
day of onset (DO); while the plasma DNA concentrations in all patients increased 
significantly on day 2 or day 3. 
The half-life of plasma DNA has been reported to be about 16 mins (Lo et al., 
1999f), therefore the second peak of plasma DNA concentration would be due to the 
continual damage of brain tissues. The disease progress of stroke is gradual, which may 
partially explain the delayed peak after 2 to 3 days. In fact, some studies have reported 
a similar pattern (i.e. peak at 2 or 3 days of onset) of S-100 and NSE proteins in blood 
after stroke (Missler et al., 1997; Wunderlich et al., 1999). As such, the source of the 
elevated cell-free DNA concentration and the protein markers released into the 
circulation may be the same. Little is known about how levels of S-100 and NSE 
proteins in blood change over time after stroke (Missler et aL, 1997). The delayed peak 
concentration may be partly resulted from the apoptosis of brain tissue since apoptosis 
takes time to occur. 
Since the sample size of present study is small, there is no correlation between 
plasma DNA concentration and neurological outcome. Whether the initial elevated 
level on day 0 or the second peak on day 2 is more significant in predicting the 
outcomes after stroke need to be elucidated in further studies on a larger population. A 
parallel study on the time course changes of the concentrations of plasma DNA, S-100 
and NSE after stroke may worth carrying out to compare their respective usefulness in 
the prognosis of stroke. 
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In conclusion, the data suggest that the concentration of plasma DNA increase 
gradually to 2 days after the onset of stroke. Measurement of plasma DNA 
concentration might be useful in monitoring the effects of therapies for the diseases. 
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CHAPTER 10 CONCLUSION AND FUTURE 
PERSPECTIVES 
Conclusion: 
The analysis of cell-free DNA in the plasma and serum has opened up a new 
area for medical diagnostics and prognostics. 
Significantly high levels of cell-free circulating DNA in pathological conditions 
e.g. cancer (Foumie et al., 1995) and organ transplant rejection (Lo et al., 1998b), have 
been shown and are closely associated with cell death. Prompted by this hypothesis, a 
study of the changes of cell-free circulating DNA concentration in the plasma 
immediately following injury was done (Lo et al., 2000c); and the results were so 
encouraging that the cell-free circulating DNA concentration seemed to be positively 
correlated with injury severity. The preliminary results have also been shown useful in 
the prediction of adverse outcomes after major trauma (Rainer et al., 2001). 
In a prospective study, chapter 6 in this thesis has shown that cell-free DNA 
concentration in plasma increases shortly after injury. The elevated concentration 
increased with injury severity; and was the highest in patients who subsequently 
developed MODS and in those died within the study period (28 days). Although the 
trend was validated, the absolute concentration of plasma DNA was found to be much 
lower than the previous finding. An alternative method may have to be established in 
order to express the results in such a way that any inefficient discrepancies generated 
from experimental procedures would be diminished. 
140 
Conclusion and Future Perspectives 
Moreover, the plasma DNA concentrations in trauma patients were found not 
affected by the choice of anticoagulant (either EDTA or heparin), nor by plasma 
filtration prior to storage or DNA extraction (Chapter 6). 
The kinetic patterns of plasma DNA concentration after trauma were described 
in Chapter 7. The elevation of plasma DNA concentration started as early as twenty 
minutes after injury and remained elevated in the first 3 hours in severely injured 
patients (ISS > 25). The raised plasma DNA concentration resolved gradually within 3 
hours in minor/moderate injured patients. With regard to severely injured patients who 
need the care of ICU, the mean plasma DNA concentration decreased in a faster rate in 
those did not develop MODS than those went on to develop MODS. Mean plasma 
DNA concentration in patients without MODS fell 99% on day 2 from the initial level 
on the day of injury to a level near normal baseline, whereas the level decreased slowly 
during the first week in patients with MODS. 
The initial elevation of plasma DNA concentration may be due to the 
spontaneous release of cell-free DNA from injured tissues, whereas subsequent (up to 
28 days) persistently higher level of plasma DNA concentration in patients who 
developed MODS may due to the impaired clearance capacity of organ systems 
influenced by the imbalance of hormone after the traumatic insults. 
Stroke is another major clinical problem commonly encountered in the 
emergency room. It is recognized as one source of brain tissue injury as a result of cell 
death from hypoxia. Chapter 8 illustrated the aberrant quantitative change of plasma 
DNA after acute stroke. The phenomenon and pattern discovered has never before been 
described in stroke patients. The change started early — within 24 hours - from the 
onset. The plasma DNA concentration correlated with stroke severity assessed by GCS, 
but not the NIHSS. However, for patients with NIHSS > 8, the plasma DNA 
141 
Conclusion and Future Perspectives 
concentrations in patients survived within 28 days or 6 months was significantly higher 
than those died. 
Further important differences were found in the outcomes. Outcomes after 
stroke have been measured as mortality at 28-day, mortality at 6-month and disability 
assessed by the Post-Stroke Modified Rankin Score (PR) at 6-month. The plasma DNA 
concentrations in patients who died (either at 28-day or 6-month) were about double 
that of the survivors. Patients with more severe disability (PR >2) also gave a slightly 
but significantly higher plasma DNA concentration than those have much recovery (PR 
=0-2). From the ROC curve analysis, plasma DNA concentration is a good potential 
predictor for stroke outcome especially to predict the early mortality i.e. mortality 
within the first 28 days from the stroke onset. In addition, plasma DNA concentration 
was able to differentiate the mortality and disability of stroke patients with normal or 
negative neuroimaging. The differences of plasma DNA concentrations between those 
died and severely disabled were significantly higher than those survived and without 
much disabilities. 
On the other hand, plasma DNA concentrations among patients of different 
types of stroke (infarct, haemorrhagic and TIA) did not show much differences, 
suggesting that it may be the severity and magnitude of the insult rather than the cause 
itself that would determine the final outcome. 
The daily measurement of plasma DNA concentrations on 5 stroke patients 
show significant variations, and a second peak on day 2 (2 days following the onset) can 
be observed. This followed a similar pattern of si00 and NSE protein concentration in 
the blood (Missler et al., 1997; Wunderlich et al., 1999), which may suggest both cell-
free DNA and the protein markers are released from the same source into the 
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circulation. The delayed peak concentration also suggest the cell-free DNA and 
proteins were released from apoptotic mechanism. 
Hence, although both mechanical trauma and acute stroke involved tissue injury, 
the mechanisms for the elevation of plasma DNA concentration underlying both 
situations were different. The cell-free DNA released after trauma may due to necrosis, 
from tissues directly damaged from trauma; whereas apoptosis may be the major cause 
after stroke. 
Studies in this thesis have several limitations. The data were obtained from a 
single academic hospital setting and therefore may not be generalized to other settings. 
The sample sizes in some of the studies were small, for example, there were only 5 
patients enrolled in the daily serial study of plasma DNA concentration after stroke. 
Furthermore, patients recruited in the studies were not evenly distributed among various 
conditions such as the number of patients who suffered from severe trauma were lower 
than the minor/moderate group; less than 10 trauma patients who died few days after the 
trauma could be recruited (Chapter 6 and 7); and the number of patients with severe 
stroke or poor outcomes were smaller than the mild group. All these may partly reflect 
that the present medical treatments and technology are very good and advanced so both 
mortality and morbidity can be reduced. Finally, the patients in both the trauma and 
stroke studies were heterogeneous. There were a wide range of age, unbalanced sex 
groups, different health statuses and background of medications; variations of the time 
of onset to blood sampling. These are problems always encountered in clinically-base 
studies. 
It is widely accepted that patient survival is increased if the disease progression 
can be predicted as early as possible, so preventive treatment can be provided in 
advance. Quantitative analysis of plasma DNA as shown in this thesis was able to show 
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its usefulness to predict outcomes during the very earlier stage of the disease onset. 
Besides, these studies have initiated the molecular diagnostic and prognostic 
possibilities in emergency medicine. 
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Future perspectives: 
Although the studies in this thesis have demonstrated increases in plasma DNA 
in patients early after trauma and stroke, correlated changes with severity and predicted 
mortality and morbidity, there are no studies investigating circulating RNA in patients 
after trauma and stroke. Unlike DNA, RNA is present in much larger quantity, in the 
cytoplasm and ribosomes of cells, and may therefore be released earlier than DNA 
which normally exists in the nucleus. Circulating RNA has recently been demonstrated 
in the plasma/serum of healthy subjects (Tsui, Ng & Lo, 2002), cancer patients (Lo et 
al., 1999a; Kopreski et al, 1999; Chen et al., 2000; Silva et al., 2001) and in pregnancy 
(Ng et al., 2003b; Ng et al., 2003a). DNA itself is a non-specific molecular marker 
which is normally present in all eukaryotic cells. RNA, on the other hand, is tissue 
specific due to different gene expression in different tissues and cells. Thus the 
detection of different RNA in the circulation may give an insight on affected tissues and 
organs. Since S-100 protein and NSE were found to be neuronal cell specific and up-
regulated after stroke, the S-100 and NSE RNA may also be measured in the blood. 
From the trauma studies in this thesis, major head injury was found to be the main site 
of injury (45%). Therefore in future studies, it may worth measuring and comparing 
quantitative changes in si00 and NSE RNA in patients suffering from major head injury 
and those suffering from acute stroke. 
It should be of great interest to further investigate the molecular characteristics 
of the cell-free nucleic acids released from trauma and stroke. The sizes of the DNA in 
plasma may provide evidence on whether the DNA has resulted from apoptosis or 
necrosis because apoptosis normally produce a DNA length around 180 base-pairs, 
fragmented by caspase-activated DNase in the multiples of nucleosomal DNA (Nagata, 
2000). Inflammatory response leading to ALI, ARDS and MODS after major trauma 
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are believed to be regulated by apoptosis (Matute-Bello et al, 1997). Apoptosis 
provides a way of removing neutrophils from an area of inflammation with minimal 
damage to the surrounding tissue. Therefore, by investigating the nature of plasma cell-
free DNA, we may know the apoptotic conditions inside the body and the chance of 
developing the organ failure. 
Therefore, further investigation of the nature of cell-free nucleic acids allows an 
even better understanding to the complications after tissue injury and opens new 
therapeutic opportunities. Other clinical problems involving tissue injury e.g. 
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APPENDIX 1 GORIS，MULTIPLE ORGAN FAILURE 
SCORE 
System Clinical features 
Pulmonary Failure 0 No mechanical ventilation 
1 Mechanical ventilation and PEEP < 10cm H2O, and FiO: <0.4 
2 Mechanical ventilation and PEEP > 11cm H2O, and FiO: > 0.4 
Cardiac Failure 0 Normal BP; no vasoactive substances 
1 Hypotension (�lOOmmHg) requiring volume loading 
e.g. dopamine (< lOjug/min = lOmL/hour) or GTN (< 20|Lig/min) 
2 Hypotension (< 1 OOmmHg) 
e.g. dopamine (> 10|Lig/min = lOmL/hour) or GTN (> 20|ug/min) 
Renal Failure 0 Serum creatinine < 2mg/dL [< 180)amol/L] 
1 Serum creatinine > 2mg/dL [> 180|Limol/L] 
2 Haemodialysis or peritoneal dialysis 
Hepatic Failure 0~ SGOT < 25 units/L and a total bilirubin < 2mg/dL [< 
33|imol/L] 
1 SGOT 25-49 units/L or bilirubin 2-6mg/dL [33-100|Limol/L] 
2 SGOT > 50 units/L or bilirubin > 6mg/dL [> 100|imol/L] 
Haematol Failure 0 Normal counts of thrombocytes and leukocytes 
1 Thrombocyte count < 50x10^/L and/or leukocyte count of 30-
60x10^/L 
2 Haemorrhagic diathesis, or leukocytes < 2.5x10^/L, or 
leukocyte count > 60x10^/L 
G-I Failure 0 Normal 
1 Acalculous cholecystitis or stress ulcer 
2 Bleeding from stress ulcer requiring > 2 units blood, 
necrotizing enterocolitis and/or pancreatitis, and/or spontaneous 
perforation of the gallbladder 
CNS Failure 0~ Normal 
1 Clearly diminished responsiveness 
2 Severely disturbed responsiveness and/or diffuse neuropathy 
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PEEP ： positive end-expiratory pressure 
Fi02： nitroglycerin 
BP: Blood pressure 
SGOT: serum glutamic-oxaloacetic transaminase 
G-I: Gastrointestinal tract 
CNS: Central nervous system 
(Goris et al, 1985) 
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APPENDIX 2 DEFINITIONS AND CRITERIA FOR 
ARDS, ALI AND MODS 
Acute respiratory distress syndrome (ARDS): ARDS is defined as 
an acute inflammatory syndrome characterized by Bernard (Bernard 1994) as: 
1. impaired oxygenation defined as a ratio of the partial pressure of arterial oxygen 
(PaOi) to the fraction of inspired oxygen (FiCh) that is < 200 regardless of the use of 
positive end-expiratory pressure (PEEP), AND 
2. bilateral pulmonary infiltrates on the frontal chest radiograph, AND 
3. a pulmonary artery occlusion (or ‘wedge，）pressure < 18 mmHg or no clinical 
evidence of elevated left atrial pressure on the basis of chest radiograph and other 
clinical data. 
ARDS has been defined by Murray as a lung injury score (LIS) of greater than 
2.5. The LIS is derived in the following way. Four parameters, each scoring from 0-4, 
are summed and then divided by the number of criteria used. The parameters are the 
extent of chest radiograph infiltrate, pulmonary compliance, ratio of arterial oxygen 
tension to inspired oxygen ( P a O � / FiO�)，and level of positive end-expiratory pressure 
(PEEP) used. 
For the purpose of this thesis, ARDS was not diagnosed until > 48 hours after 
injury to exclude the possibility that some of the changes might be due to direct injury 
rather than an inflammatory response. 
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Acute lung injury (ALI): ALI is defined as an acute inflammatory 
syndrome characterized by: 
1. a Pa02 / Fi02 < 300 mmHg (regardless of peak end expiratory pressure, PEEP), 
AND 
2. bilateral infiltrates seen on frontal chest radiograph, AND 
3. a pulmonary artery occlusion (or 'wedge') pressure (Paw) < 18 mmHg, or the 
absence of clinical evidence of elevated left atrial pressure on the basis of chest 
radiograph and other clinical data. 
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APPENDIX 3 COMPUTED AXIAL TOMOGRAPHY 
AND MAGNETIC RESONANCE 
IMAGING 
To determine the exact nature and cause of the stroke-like syndrome, patients 
received a standard clinical, laboratory and imaging workup, including cerebral 
computed axial tomography (CT) without contrast enhancement (Davis, Acerman & 
Kistler 1977; Gilman 1998) and magnetic resonance imaging (MRI) including a 
diffusion-weighted MRI study (Tong, Yenari & Albers 1998; Linfante, Llinas & Caplan 
1999; Schellinger, Jansen & Fiebach 1999). 
All computed axial tomography (CT) scans were performed with a GE Hi Speed 
Advantage Unit. Axial 5/5 mm scans were done for the posterior cranial fossa and 
10/10 mm scans were then performed up to the vortex space. Magnetic resonance 
imaging (MRI) scans were performed with a 1.5 T scanner (Sonata, Siemens). The 
sequences included SE T1 axial (TR/TE/NEX 425/14/2 slice thickness 5 mm, slice gap 
0.5 mm 192x256 matrix), TSE T2 axial (TR/TE/NEX 2500/120/1 slice thickness 5 mm 
slice gap 0.5 mm 192x256 matrix), and single shot EPI diffusion-weighted axial images 
(TR=18 0 msec, TE=122 msec, slice thickness 5 mm, matrix 128x128, EPI factor of 
90). Three different diffusion gradients were used, giving b values of 0, 500 s/mm and 
1000 s/mm^. The volume of infarct was measured on both CT films and MRI diffusion 
scans, whilst the volume of an acute hematoma was measured on CT films and T1 
weighted MRI scans. 
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3 To verbal command 
2 To pain 
1 No response 
Best motor response 
6 Obeys commands 
5 Localizes to pain 
4 Flexion withdrawal 
3 Flexion abnormal 
2 Extension 
1 No response 
Best verbal response 
5 Oriented / converses 
4 Disoriented / converses 
3 Inappropriate words 
2 Incomprehensible sounds 
1 No response 
(Teasdale & Jennet, 1974) 
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APPENDIX 5 Post-Stroke Modified Rankin Scale 
Score Symptoms 
0 No symptoms at all 
No significant disability, despite symptoms; able to 
carry out all usual duties and activities 
Slight disability; unable to carry out all previous 
2 
activities but able to look after own affairs 
Moderate disability; requiring some help, but able to 
3 
walk without assistance 
Moderately severe disability; unable to walk without 
4 assistance and unable to attend to own bodily needs 
without assistance 
Severe disability; bedridden, incontinent and requiring 
5 . . 
constant nursing care and attention 
^ Death 
* sometimes death may be scored as 6. 
(Arboix et al, 2003) 
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